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3Abstract
The cloned dihydrofolate reductase gene of Saccharomyces
cerevisiae (DFR 1) is expressed in Escherichia coli. Bacterial strain
JF1754 transformed with plasmids containing DFR 1 is at least 5X more
resistant to inhibition by the folate antagonist trimethoprim.
Expression of yeast DFR 1 in E. coli suggests it is likely that the
gene lacks intervening sequences. The 1.8 kbp DNA fragment encoding
yeast dhfr activity probably has its own promotor, as the gene is
expressed in both orientations in E. coli.
Expression of the yeast dhfr gene cloned into M13 viral vectors
allowed positive selection of DFR 1 - M13 bacterial transfectants in
medium supplemented with trimethoprim. A series of nested deletions
generated by nuclease Bal 31 digestion and by restriction endonuclease
cleavage of plasmids containing DFR 1 physically mapped the gene to a
930 bp region between the Pst 1 and Sal 1 cut sites. This is
consistent with the 21,000 molecular weight attributed to yeast dhfr
in previous reports.
From preliminary DNA sequence analysis of the dhfr DNA fragment
the 3' terminus of DFR 1 was assigned to a position 27 nucleotides
from the Eco Rl cut site on the Bam Hi - Eco Rl DNA segment. Several
putative yeast transcription termination consensus sequences were
identified 3' to the opal stop codon.
DFR 1 is expressed in yeast and it confers resistance to the
antifolate methotrexate when the gene is present in 2 - 10 copies per
cell. Plasmid-dependent resistance to methotrexate is also observed in
a rad 6 background although the effect is somewhat less than that
4conferred to wild-type or rad 18 cells. Integration of DFR 1 into the
yeast genome showed an intermediate sensitivity to folate antagonists.
This may suggest a gene dosage effect. No change in petite induction
in these yeast strains was observed in transformed cells containing
yeast dhfr plasmids.
The sensitivity of rad 6 , rad 18 and wild-type cell populations
to trimethoprim were unaffected by the presence of DFR 1 in
transformants. Moreover, trimethoprim did not induce petites in any
strain tested, which normally results if dhfr is inhibited by other
antifolates such as methotrexate. This may suggest that the dhfr
enzyme is not the only possible target of trimethoprim in yeast.
rad 6 mutants showed a very low level of spontaneous petite
formation. Methotrexate failed to induce respiratory deficient
mutants in this strain which suggested that rad 6 might be an
obligate grande. However, ethidium bromide induced petites to a level
approximately 50% of that exhibited by wild-type and rad 18 strains.
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Introduction
Dihydrofolate reductase (dhfr; 5,6,7,8, - tetrahydrofolate: NADP+
oxidoreductase; EC 1.5.1.3.) is an essential enzyme which catalyzes
the NADPH dependent reduction of dihydrofolate to tetrahydrofolate
(Osborn and Huennekins, 1958). A major function of this protein is to
recycle tetrahydrofolate from the dihydrofolate which is formed in the
conversion of deoxyuridylic acid to deoxythymidylic acid (see
Figure 1). This reaction, catalyzed by thymidylate synthase (5,10 -
methylene - tetrahydrofolate: dUMP C-methyltransferase; EC 2.1.1.45),
produces stoichiometric amounts of dihydrofolate which is then
converted to tetrahydrofolate to maintain the supply of
pteroylglutamic acid cofactors (Smith and Calvo, 1982). These reduced
folate derivatives are required for one carbon transfer in various
biosynthetic reactions. These include: purine formation, thymidylate
synthesis and the anabolism of certain amino acids (primarily
methionine, serine and glycine) in a variety of organisms.
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A derivative of folic acid (N10
the formyl donor in the conversion of
formyltetrahydrofolate) is
tRNAFmet tRNAFmet
met to fmet
The latter charged transfer RNA initiates protein synthesis in
bacteria as well as in the mitochondria of eukaryotes (for a review
see Blakely, 1969). In addition to their role in protein synthesis,
folates are involved in an important way with other aspects of
macro-molecular synthesis including RNA and DNA metabolism. This
finding and the fact that folates are ubiquitous in nature has
suggested to some investigators that the vitamin might have some
regulatory function in cells (Kirschner and Bisswanger, 1976).
The parent compound, folic acid', was first isolated in pure form
Figure 1 Site of action of various antifolate drugs in the metabolic
pathway leading to the synthesis of tetrahydrofolic acid.
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from spinach (Mitchell ~~., 1944). It soon became apparent that
folates (pteroylglutamic acids) consisted of a group of over 100
closely related metabolites (Hoffbrand, 1975). More recent studies
have shown that these folates differ from the parent compound in that
they are reduced to dihydro- or more commonly tetrahydro- forms at
positions 5,6,7,8, in the pyrazine ring. Also, many folate moieties
have one of 5 single carbon units attached at N5 or N10 (see
Figure 2; Mackenzie and Baugh, 1980). In addition, in both
prokaryotic and eukaryotic systems, intracellular folates have been
found to be conjugates of pteroylglutamate consisting of chains up to
7 glutamic acid residues (Baugh and Krumdieck, 1971).
As early as the 1930's folate metabolism became an important
subject of clinical investigation when it was discovered that
sulfanilamide, a structural analogue of p-Aminobenzoic acid (pABA),
protected laboratory mice against streptococcal infections (Buttle ~
al., 1936). Subsequently, it was found that another antibiotic
trimethoprim inhibited folate metabolism, although its mode of action
was quite different from that of the sulfonamide compounds. Further
investigation revealed that sulfanilamides act as competitive
inhibitors of the pteroate synthase catalyzed condensation of PABA and
pteridine. Trimethoprim was found to be a species specific inhibitor
of dihydrofolate reductase (for a review see Wormser and Keusch,
1983).
Folate antagonists such as trimethoprim (in bacteria) and
methotrexate (in mammals), which inhibit dihydrofolate reductase
activity cause a depletion of the intracellular tetrahydrofolate
pools. This may ultimately result in "thymineless" death (Cohen and
17
Figure 2 Biologically significant derivatives of folic acid.
One carbon groups carried by tetrahydrofolate
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Barner, 1954). The loss of viab1ity due to thymidy1ate depletion
occurs in a variety of organisms from bacteria to humans (Pritikin and
Romig, 1969; Brendel and Fath, 1974; Barclay and Little, 1978; Hyrnick
and Bertino, 1973).
In addition to cell killing, thymine starvation has been shown to
be extremely mutagenic in thy- Bacillus subti1is and Salmonella
typhimurium (Bresler et a1., 1970; Holmes and Eisenstark, 1968).
Thymine1ess mutagenesis has been shown to cause specific AT - CG
transitions in Escherichia coli (Kunz and Glickman, 1985) and
bacteriophage T4 (Smith et a1., 1973). In contrast, the nuclear
genomes of yeast and cultured human cells are relatively insensitive
to mutagenesis by thymine starvation (Barclay and Little, 1978; Dimnik
and Hoar, 1983). However, high levels of mitochondrial mutation occur
in both S. cerevisiae and HeLa cell lines when grown under
"thymineless" conditions, provoked by either chemical treatment or in
mutants defective in dTMP biosynthesis, grown in the absence of the
nucleotide. The induction of respiratory deficient mutants or
"cytoplasmic petites" (p-) in yeast has also been observed after
exposure to a variety of chemical mutagens (for a review see Oliver,
1977). Thymine deprivation has also been shown to induce
recombination in~. coli (Gallant and Spottswood, 1964), in yeast
(Barclay and Little, 1978) and in mouse cells (Hori ~ a1., 1984).
The toxicity associated with folate depletion has been exploited
clinically for many years in the treatment of various human pathogens.
Dihydrofo1ate reductases from bacterial and mammalian sources exhibit
different binding affinities to various folate analogues (Baccanari
et a1., 1975). Thus, evidence has been presented by Burcha11 (1983)
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that bacterial dhfr binds trimethoprim more readily than does its
mammalian counterpart. It is this differential binding affinity which
results in a high therapeutic index for trimethoprim even though its
target is common to host and parasite.
In addition to the use of inhibitors of folate biosynthesis as
antibacterial agents, these compounds are important clinically in
cancer therapy. It appears that folic acid derivatives play some
important role in the maintenance of rapid growth and division of
neoplastic cells. The high demand of cancer cells for dietary folate
has been well documented (for a review see Hitchings, 1983). As a
consequence, the inhibition of folate metabolism by drugs such as
methotrexate and aminopterin have for many years proven to be a
clinically useful approach to the treatment of certain cancers
(Conduit, 1971). Protocols which use antifolates have evolved either
as a treatment of choice for various cancers or as an adjuvant to
surgery or radiotherapy (Bertino, 1979).
There are several physiological properties of the target cell,
which influence the relative ability of methotrexate to inhibit cell
growth (Gallivan, 1979). These include the capacity of the cell to
transport methotrexate across the cell membrane and the maintenance of
an intracellular drug concentration which is sufficient to inhibit
dihydrofolate reductase activity (Sirotnak and Donsbach, 1974). A
complication in the clinical pharmacology of the drug arises from the
finding that methotrexate, like naturally occuring folates, can be
converted to polyglutamate derivatives both in normal and tumour cells
(Nair and Baugh, 1973). Thus, it is unclear whether methotrexate
itself or a polyglutamated derivative of the drug is the actual dhfr
21
inhibitor in vivo. Because folate depletion affects preferentially
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rapidly dividing cell types, methotrexate toxicity is not limited to
neoplastic cells, but also effects those of the gastric mucosa, hair
follicule and haematopoetic system. This non-specific inhibition is
the probable cause of the side effects associated with the use of the
drug in cancer chemotherapy (ie. nausea, hairloss and anemia).
In spite of these side effects the use of methotrexate as a
cancer therapy has long been shown to be efficacious in slowing the
rate of progress of the disease and in some cases malignant neoplasms
have gone into remission after repeated administration of the drug.
However, in many instances, repeated drug use has been associated with
the emergence of methotrexate-resistant variants within the tumour
cell population. These cells fail to respond to further antifolate
therapy and the clinical course of the disease is resumed (Bertino
~ al., 1963). In an attempt to cope with an emerging drug-resistant
tumor cell population, combination chemotherapies were developed in
which other drugs such as 5-fluorouracil (which is converted in cells
to FdUMP, an inhibitor of thymidylate synthase) were used in concert
with antifolates. Paradoxically, studies in tissue culture have
yielded conflicting reports as to whether methotrexate and
5-fluorouracil (5FU) are additive or antagonistic in their action
(Ullman et al., 1977). In spite of this apparent contradiction, the
use of methotrexate and 5FU in combination has been relatively
successful in the management of many different cancers (for a review
see Morrow, 1983). Nevertheless, drug-resistant tumour cell lines
still emerged (Vesely and Cihak, 1973).
In spite of the various limitations in their use, folic acid
antagonists have proven to be one of the best available choices of
chemical substances in cancer chemotherapy. For this reason, there
is considerable interest in studies designed to increase our
understanding of the mechanisms of resistance to these compounds. The
results of numerous investigations which attempted to reconstruct in
tissue culture, the conditions under which methotrexate is used
clinically, have revealed that drug-resistance can be acquired in
three general ways: 1) an increase in the level of dhfr enzyme in the
cell (Shields, 1978); 2) a decrease in cell permeability to the
antifolate (Frei ~~., 1984) or 3) a decrease in the affinity of the
target enzyme for methotrexate (Simonsen and Levinson, 1983). The
first mechanism of resistance is the best understood at the molecular
level. In these cell lines, enzymatic activities were elevated as much
as 3000 fold and result from an increase in the number of molecules
per cell (Bastow et al., 1984). Littlefield (1969) has shown that
hybrids between wild-type and overproducing lines were intermediate in
activity which suggests that the increase in enzyme activity was not
due to a diffusible repressor. This indicated that overproduction of
dhfr unlike the situation which has been observed in procaryotes, can
not be ascribed solely to regulatory mutations (Smith and Calvo,
1982). It was revealed subsequently that many of these MTX-resistent
lines arose as a consequence of gene amplification (Heintz and Hamlin,
1982; Schimke, 1984).
Alt et al., (1978) demonstrated that in at least two cases
overproduction of dihydrofolate reductase in response to a
methotrexate challenge resulted from an increase in copy number of the
structural gene for the enzyme. In one of these variants the
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dihydrofolate reductase gene had been amplified over two hundred fold
and was localized within a homogeneously staining chromosomal region.
Furthermore, Nunberg et a1., (1978) using in situ hybridization
-- ---
studies have confirmed that the amplified dihydrofo1ate reductase
genes were specifically localized to these homogeneously staining
regions. This type of methotrexate resistant cell retains its
phenotype in the absence of any selection (Shimke, 1984). In contrast
to these isolates, another type of gene amplification event, which is
located on double minute chromosomes, resulted in an unstable drug
resistance phenotype (Kaufman ~ a1., 1979).
Several models have been advanced to explain the occurrence of
gene amplification events in methotrexate-treated eucaryotic cells.
Varshavsky (1981) has suggested that replicon "misfiring" might lead
to precocious synthesis of chromosomal domains adjacent to DNA
replication origins. The extra copies of the dihydrofo1ate reductase
gene which accumulate during growth in the presence of the drug confer
a selective advantage to host cells. A prediction of this model is
that the dihydrofolate reductase amplified region must be in close
proximity to an origin of DNA replication. This was shown to be the
case in Chinese hamster ovary cells (Heintz and Hamlin, 1982). Once
the dihydrofolate reductase gene region has been duplicated by this
mechanism, it is supposed that subsequent amplification events occur
by unequal mitotic crossing over (Banerjee and Benedict, 1979).
Recently Barclay ~ a1., (1982) have shown that the depletion of
intracellular pools of thymidylate by antifolate drugs results in a
large increase in the rate of mitotic crossing-over in yeast. In this
study, an increase in recombination frequency of over 500 fold was
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observed in yeast populations treated with methotrexate (Barclay et
~., 1982) and in cells cultured in the presence of FdUMP, the
metabolically active derivative of 5-fluorouracil (Kunz ~ al., 1980).
Thus, these authors have suggested that methotrexate might induce
resistance to itself by promoting genetic rearrangements in target
cells.
Although it is a somewhat perilous exercise, in general terms, to
extrapolate results directly from one species to another, studies in
yeast have been used as a basis for designing similar experiments in
animal cells. Since yeasts are intermediate in biological complexity
relative to bacteria and mammals, they are being used ~or basic
studies in eukaryotic biology including those of gene expression, DNA
replication, recombination, transposition, chromosome segregation,
chromatin structure and control of cell mating type (for a review see
Petes, 1980; Struhl, 1983).
Thus, the bakers yeast Saccharomyces cerevisiae is an excellent
experimental system for genetic and biochemical analysis of folate
metabolism. Yeast ,cells can be easily manipulated by classical
microbiological techniques and more recently by the very powerful
recombinant DNA methods. Thus, it has been possible to reveal some
aspects of the genetic consequences of folate depletion in this
organism, which have been difficult to analyze directly in human
cells.
For example, since yeast is a facultative anaerobe, lesions
occurring in either the nuclear or the mitochondrial genome can be
readily distinguished. Damage to yeast mitochondria is easily
monitored (Goldwaite ~ a1., 1974). Thus, this system is ideal for
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studying the effects of the cloned dhfr gene under folate deprived
conditions. Another important consideration in choosing yeast as a
model system for studies of folic acid biosynthesis in eukaryotes, is
the finding that some folate interconversion enzymes exist in 2 forms;
an enzymatic activity isolated in the cytoplasm and an analogous
function associated with the mitochondrion (Luzzati, 1975). Thus it
is advantageous in these experiments to be able to distinguish easily
the expression of nuclear from mitochondrial gene products.
One of the difficulties encountered in studying folate metabolism
in S. cerevisiae has been the paucity of useful information on yeast
dhfr. Although an extensive-genetic map of the 17 chromosomes on S.
cerevisiae is available (Mortimer and Schild, 1980) the map position
of the dhfr locus remains unknown. Furthermore, no dihydrofolate
reductase deficient mutants of ~ cerevisiae (which would be of
considerable utility in biochemical studies) are known to exist.
Use of the cloned gene would greatly facilitate both the isolation of
a dhfr gene disruption and determination of the position of the gene
in the yeast genome.
Yeast is also well suited for studies of dihydrofolate reductase
expression due to the sophisticated genetic system which has been
developed in this organism over many years. By the analysis and
manipulation of yeast genes ~ vitro and in ~. using recombinant DNA
technology, the control of the expression of numerous yeast genes is
now well understood, at the molecular level (Andreadis et al., 1984;
Holland and Holland, 1979; Mantsala and Zalkin, 1984; Zaret and
Sherman, 1982). At the present time there exist simple and general
methods for the isolation and subsequent amplification on multicopy
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plasmids of virtually any yeast gene. The cloning of specific DNA
segments allows one to study the expression and organization as well
as the regulation of individual and co-regulated gene sets. The
details and applications of these techniques have been extensively
reviewed (Botstein and Davis, 1982).
A prerequisite to understanding the mode of action of a cloned
gene in vivo is that the said gene be returned to the organism of
origin. Relatively simple methods have been developed by which
cloned DNA can be introduced into yeast spheroplasts, or into intact
cells treated with lithium chloride. This DNA can be maintained in
the host cell in various ways: 1) integrated into a specific location
in the genome; 2) as an extrachromosomal element on a multicopy
plasmid ;or 3) stably maintained on "minichromosomes" containing one
of several cloned yeast centromeric regions (for a review see, Hinnen
et al., 1978).
As mentioned previously, one of the advantages of yeast as an
experimental system resides in the extensive catalogue of yeast
mutants which are available for study. For example, there are nearly
100 different loci in S. cerevisiae which modify the response of
strains to mutagenesis by chemicals or radiation (for a review see
Haynes and Kunz, 1981). Enhanced sensitivity to either UV light or
ionizing radiation occurs in strains carrying mutant alleles of these
genes (Resnick, 1969). These radiation sensitive genes have been
classified into three epistatic groups, which correspond to three
distinctive modes of DNA repair (for a review see, Game, 1983).
The Rad 6 and Rad 18 genes of S. cerevisiae are 2 of the at least
9 genes thought to be involved in the error-prone dark repair system
of UV induced pyrimidine dimers (Game, 1983). Even though the precise
function of the Rad 6 gene product is unknown, it has been shown that
mutagenesis in ~ cerevisiae by both chemical and physical agents
requires a functional RAD 6 gene (Lawrence and Christensen, 1976;
Prakash, 1974). An unusual property of both rad 6 and rad 18 mutant
strains is that they are strongly inhibited by the antifolate
trimethoprim. These findings are intriguing since there is no obvious
relationship between radiation sensitivity and folate metabolism.
Furthermore, mutant strains carrying both rad 6 and rad 18
exhibit a high frequency of spontaneous mutation to trimethoprim
resistance accompanied by metabolic suppression of UV-induced death.
This suggests that there are 2 activites associated with these
mutations: 1) wild-type radiation repair and resistance to
trimethoprim; and 2) induced mutagenesis.
In general, the primary focus of this study was to begin the
characterization of the cloned dihydrofolate reductase gene of yeast
in the radiation sensitive mutant and other yeast strains. By
transforming rad 6 and rad 18 mutants with the dhfr gene on multicopy
plasmids, it should be relatively easy to determine whether the
trimethoprim sensitivity of these strains arises as a consequence of
decreased dhfr activity. It was hoped that by the use of the cloned
gene on integrating vectors and multicopy plasmids it would be
possible to gain insight into the regulation of folate metabolism in
this simple eukaryote.
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Materials and Methods
The strains of Escherichia coli and Saccharomyces cerevisiae
used throughout the course of this study are summarized in Tables 1
and 2.
Media and Buffers
For routine growth of bacterial strains either L medium or B
medium was used. L medium contained per litre: 10 g bacto-tryptone,
5 g bacto-yeast extract and 5 g NaCl, whereas B medium contained per
litre: 10 g bacto-tryptone, and 8 g NaCl. Minimal media (MIN)
0.5 g sodiumcitrate.2H20, 1.0 ml of a 20% MgS04.7H20 stock solution
and 10.0 ml of a 20% dextrose stock solution*. Appropriate
nutrients were added at a final concentration of 50 ug/ml with the
exception of thiamine hydrochloride** which was added at a final
concentration of 5 ug/ml. Antibiotics were added to media at 48°C
after autoclaving at final concentrations of: ampicillin 50 ug/ml,
chloramphenicol 30 ug/ml, neomycin sulphate 200 ug/ml and tetracycline
150 ug/ml. Where needed, trimethoprim was added to MIN medium at a
final concentration of either 2 ug/ml, 100 ug/ml or 500 ug/ml. Unless
otherwise indicated, bacto-agar was added at a final concentration of
2% for plates and 0.6% for soft agar.
YPDP medium was used for routine growth of yeast strains. This
contained per litre: 10 g bacto-yeast extract, 20 g bacto-peptone,
20 g dextrose, and 1.5 g KH2P04- Minimal medium (SD) contained per
* added after autoclaving.
** filter sterilized separately_
Table 1 Escherichia coli strains used.
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Strain
JF1754
JM103
Genotype
his B, leu B, met B,
hsd r-, hsdm+, lac,
gal, rec A,
sbc B 15, hsd R 4,
~ E, F'tra D 36, hsd m+
pro AB, lac 1 Z Mi5, hsd r-
Source
J.Freisen
Bethesda
Research
Laboratories
Table 2 Yeast strains used in this study.
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Strain
AH 2
LP2730-1A
LP2729-4B
Genotype
Mat a,,o+, leu 2-3,
leu 2-112, his 4
Mat a,p+, leu 2-3,
leu 2-112, hi! 3-1,
trp 1-289, ura 3-52,
rad 6-1
!!!.! a,p+, leu 2-3,
leu 2-112, ~ 3-1,
trp 1-289, ura 3-52,
rad 18-2 --
Source
R.Storms
L.Prakash
L.Prakash
litre: 6.75 g bacto-yeast nitrogen base without amino acids and 20 g
glucose. Appropriate nutrients were added at a final concentration of
L-histidine-HCl 20 ug/ml, L-leucine 30 ug/ml, L-tryptophan 20 ug/ml
and uracil 20 ug/ml. Trimethoprim was added to SD medium as required.
YPGP medium contained 3% glycerol in place of dextrose. dTMP and
Geneticin (G418) were added to molten media at 48°C after autoclaving.
Unless otherwise stated, the dTMP concentrations were as follows: in
YPDP 100 ug/ml and YPGP 200 ug/ml. G 418 was added to both YPDP and
YPGP at a final concentration of 150 ug/ml.
Plasmid DNA was maintained or dissolved in either TES buffer or
TE buffer. TES buffer contained per litre: 20 roM Tris-HCl pH 7.5,
10 roM NaCl and 0.1 mM EDTA pH 7.5, whereas TE buffer contained per
litre: 10 mM Tris-HCl and lmM EDTA adjusted to a pH of either 7.5 or
8.0. Yeast cells were washed in a O.lM phosphate buffer (pH 7.0).
Chemicals
Restriction endonucleases, nuclease Bal 31 and T4 DNA ligase were
obtained from Boehringer Mannheim. Nucleotide reagents, M13 single
stranded primer and Klenow fragment were purchased from P. L.
Biochemicals Inc. and Bethesda Research Laboratories. Trimethoprim,
sulfanilamide, methotrexate, and ampicillin were from Sigma Chemical
Co. All culture media and remaining chemicals were purchased from
Difco and BDH Chemicals with the exception of Glusulase which was
obtained from Endo Laboratories.
Rapid Plasmid Preparation
The method used to characterize plasmid DNA in E. coli was a
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modified procedure of Birnboim and Doly (1979). Cells from a single
clone were grown overnight with gentle shaking at 37°C in L media
supplemented with the appropriate antibiotic. Approximately 1.0 ml of
culture was transferred to a 1.5 ml microfuge tube and the cells were
harvested by centrifugation at 12K for 30 sec (Beckman Microfuge 12).
The supernatant was decanted and the cells resuspended in 0.2 ml of
freshly prepared cold lysis solution (50 mM glucose, 10 roM EDTA (pH
8.0), 25 roM Tris-HCI (pH 8.0) and 2.0 mgjml lysozyme) by vortexing.
This cell suspension was left on ice for at least 30 min, after
which 0.4 ml of alkaline SDS solution (0.2 M NaOH and 1% SDS) was
added to the tubes. The contents were mixed occasionally by inversion
and left on ice. After 5 min, 0.3 rol of cold 3.0 M Na acetate (pH
5.0) was added to this viscous solution and the microfuge tubes were
left on ice for at least 30 min or until a heavy white precipitate
formed. The suspension was then centrifuged at 12K for 5 min at 4°C
and the supernatant was transferred to a clean microfuge tube. 1.0 ml
of isopropanol prechilled to -20°C was added to the supernatant and
the microfuge tubes were then placed at -20°C for at least 30 min or
at -70°C for 15 min.
The precipitate was recovered by centrifugation at 12K for 2 min
at 4°C and the pellet was dissolved in 100 ul of 0.1 M Na acetate (pH
5.0). One ml of 95% ethanol was added to the suspension and the
sample was left at -70°C for 10 min. The precipitate was recovered as
before and the resulting pellet was washed with 70% ethanol prechilled
to -20°C one or two times. The ethanol was decanted and the pellet
dried in an incubator at 37°C for 15 min. The DNA was then resuspended
in 20 ul of TE buffer.
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Treatment with 1.0 ul of a 10 ug/ml DNAse-free RNAse solution (in
10 mM Tris HCI pH 7.5, 15 roM NaCI) for 15 min at -20°C was optional,
depending on the future disposition of the sample. This DNA was stored
at 4°e until it was used in restriction map analysis, tranformation or
cloning.
Large Scale Preparation of Plasmid DNA
For the isolation of plasmid DNA in larger amounts a modified
alkali SDS procedure was used (Maniatis ~ ~., 1982). Cells from a
single bacterial colony harbouring the desired plasmid were grown
overnight with gentle shaking at 37°e in L media supplemented with the
appropriate antibiotic. 100 ul of the overnight culture was added to
25 ml of fresh media and grown at 37°e until cells entered late log
phase (OD600 = 0.6A). These cells were then used to inoculate 500 ml
of supplemented L media and grown as before to an OD600 of 0.4A
(approximately 3 hr). To allow for an increase in the ratio of
plasmid/chromosomal DNA either chloramphenicol (30 ug/ml) or
spectinomycin (300 ug/ml) was added to the culture which was then
incubated for an additional 12 - 16 hr.
Bacterial cells were harvested by centrifugation at 10K for 10
min at 4°C in an I.E.C. B-20A centrifuge (A-54 rotor). The supernatant
was decanted and the bacterial pellet resuspended in 8.0 ml of freshly
prepared lysis solution (50mM glucose, 10 roM EDTA pH 8.0, 25mM EDTA pH
8.0 and 5 g/ml lysozyme) prechilled to -20 oe. The suspension was
transferred to a 45 ml Oakridge tube and left at room temperature for
5 minutes. All subsequent steps were carried out on ice unless
otherwise stated. 16 ml of freshly made alkaline SDS solution (0.2 N
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NaOH, 1% SDS) was added to the suspension and the test-tube was
inverted occasionally to mix the contents thoroughly.
After 10 min, or until the contents became viscous, 12 ml of
3.0 M Na acetate (pH 5.0) prechilled to -20°C was added. After a
minimum of 15 min the sample was centrifuged at 16K for 20 min at 4°C
in an I.E.C. B20A centrifuge (A-211 rotor). A minimum of 25 ml of
supernatant was transferred to a fresh Oakridge tube and isopropanol
was added to 0.54 v/v. The solution was throughly mixed and left on
ice for at least 15 min. DNA was collected by centrifugation at 16K
for 30 min at 4°C as before. The supernatant was decanted and the
pellet washed with 30 ml of 75% ethanol prechilled to -20°C. Care was
taken to ensure that the pellet was not disturbed during this step.
The ethanol was decanted and the pellet dried in a 37°C incubator,
after which the pellet was resuspended in 7.0 ml of TE buffer.
Further purification of plasmid DNA was carried out by cesium-chloride
density gradient centrifugation.
Preparation of Cesium-Chloride Density Gradients
7.0 ml of plasmid DNA solution was transferred to a 16 x 76mm
ultra-clear ultracentrifuge tube which contained 7.5 g of CsCl. The
tube was covered with parafilm and inverted until all CsCl was
dissolved. 0.5 ml of a 5 mg/ml ethidium bromide (EtBr) solution was
added to the top of the tube and any air bubbles were displaced with
paraffin oil. Care was taken to ensure that the ultra-centrifuge tube
assembly was air-tight before the tube was inverted to mix the EtBr
with the CsCl solution. All subsequent steps were done in the dark,
to prevent photolysis of the DNA/EtBr complex.
35
The plasmid preparation was then centrifuged at 40K in an I.E.C.
B-60 ultra-centrifuge (A-321 rotor) for a minimum of 48 hrs at 23°C.
Recovery of Plasmid DNA
The ultra-centrifuge tube was mounted onto a retort stand and the
DNA bands were viewed under long wavelength UV light. A 1.0 ml
disposable syringe with a large gauge needle was inserted just below
the plasmid DNA band (lower band). To facilitate removal of the
plasmid DNA a smaller-gauge needle was inserted into the ultra-
centrifuge tube immediately below the cap assembly. EtBr was removed
by extracting the plasmid DNA with equal volume of l-butanol at least
3 times. The DNA sample was then dialyzed against 3 changes of 100
volume excess TE buffer for at least 6 hours each at 4°C. After this
the DNA concentration and purity were determined in a Beckman DU-7
Spectrophotometer. The biological activity of the DNA was determined
by its transformation frequency and then stored at 4°C until use.
Preparation of Competent Cells
E. coli cells from a single clone were added to 2 ml of L media
broth and grown overnight with gentle shaking at 37°C. Depending upon
the volume of competent cells required the overnight culture was then
diluted 1:100 in fresh L media and incubated at 34°C to an ODSOOof
0.6 - 1.0.
Cells were harvested by centrifugation at 2.7K for 5 min at 4°C
in an I.E.C. clinical centrifuge (model Centra-7R). The supernatant
was decanted and the pellet resuspended in one-half the growth volume
of 50 mM CaCl 2 prechilled to -20°C. The suspension was kept on ice for
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at least 20 min, after which the cells were collected and the pellet
gently resuspended in 1:10 original growth volume of SOmM CaCl2 as
before. These cells were stored on ice or at 4°C for period of up to
48 hrs prior to being used. Since competent cells are extremely
fragile, care was taken to avoid vortexing or centrifugation of cells
except as stated previously.
Transformation of E. coli
For each transformation, 200 ul of competent cells were needed to
which 1.0 ug of plasmid DNA from rapid preparation or approximately
50 ng of plasmid DNA from large scale preparations were added. The
suspensions were left on ice for at least 60 min after which the
entire 200 ul sample was spread onto the appropriate agar plate.
These plates were then incubated at 37°C for a minimum of 6 hrs to
determine the number of transformants lug DNA.
Restriction Endonuclease Digestion
Plasmid DNA was digested with restriction enzymes in the
appropriate buffer under the conditions described by the manufacturer
or as suggested by Maniatis et ~., 1982.
Ligation of DNA Fragments
The conditions for "sticky-end" and "blunt-end" ligations have
been described previously (Maniatis et al., 1982). The molecular
--
concentration of DNA was determined by use of the following equation.
p mol ends/ ug DNA = 2 x 106 x N
M
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where 2 the number of ends per linear molecule, 106 = conversion
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factor, N = the number of cut sites + 1 for linear DNA, or the number
of cut sites for circular DNA and M the number of base pairs x 666
glmol (at 50% AT). For maximum cloning efficiency a 3 fold p mol end
excess of fragment DNA over vector DNA was used.
Agarose Gel Electrophoresis
The standard method used to separate, identify and purify DNA
fragments was electrophoresis through agarose gels. As little as
1.0 ng of DNA can be detected by direct examination of the gel in UV
light (Sharp et a1., 1973).
--
To prepare agarose gels the appropriate amount of agarose which
was dependent upon the size of the DNA fragments to be separated (see
Maniatis et al., 1982) was added to TBE buffer (90 roM TRIS-borate,
90 mM Boric acid, 2 roM EDTA) and the suspension was boiled 3 times.
The gel was poured into the desired mould, the comb inserted and the
gel allowed to solidify. Sufficient TBE buffer to cover the gel to a
minimum depth of 1.0 mm was added after which the comb was carefully
removed to minimize damage to the wells. The samples were then loaded
into the appropriate pockets of the submerged gel as quickly as
possible to minimize diffusion of the DNA samples into the agarose
surrounding the pockets. The gels were run at a constant voltage of
70 V until the bromophenol blue portion to the tracking dye (25%
glycerol, 0.2% xylene cyanol, 0.2% bromophenol blue) had migrated
approximately two-thirds down the length of the gel. This was
generally between 2 - 5 hrs, dependent on the agarose concentration of
the gel and the size of DNA fragments being separated.
After the electrophoresis was complete the gel was placed into
TBE buffer containing 0.2 ugjml of EtBr for approximately 5 min. The
gel was rinsed with tap water to remove any surface EtBr and then
photographed.
Gel Photography
The stained gel was fluoresced under UV illumination provided by
a Chromato-Vue Transilluminator (Model TM-15) and photographed using
an Omega-View 45E camera fitted with a Nikkor-W 150 mm lens and a
light-pass UV block Wratten filter. The film used was Polaroid High
Speed 4 X 5 land film, Type 57 (ASA 3000). Generally an exposure time
of 2 - 5 sec and a developing period of 30 - 45 sec was sufficient to
obtain good resolution of the bands.
Restriction Map Analysis
Once photographed th.e gel was ready to be analysed. All linear
measurements were made from the origin (cathode end) to the mid-point
of the migrating band. The distance each band had migrated (in cm)
was recorded. Actual DNA fragment sizes were determined using a
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commercially obtained "
al., 1982).
phage marker DNA" as described (Maniatis et
Localization of the Yeast DFR 1 Gene
Approximately 10 ug of pIUD-1 DNA was digested with either Bam H1
or Sal 1 to completion under previously mentioned conditions. DNA was
ethanol precipitated and collected as before, except that 0.2 M NaCl
was used in place of 0.3 M Sodium Acetate. The pellet was resuspended
in 180 ul of Bal 31 reaction buffer (12 mM CaC12' 12 mM MgCl, 600 mM
NaCI, 20 roM Tris HCI pH 8.1, 1 mM EDTA) placed at 30°C and allowed to
equilibrate for 5 min. 10 units of Bal 31 nuclease was added to the
sample which was then mixed throughly and immediately placed back at
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30°C. 10 ul aliquots were removed at t o and at 30 sec intervals
thereafter. To stop Bal 31 digestion 3 ul of 200 mM EDTA was added to
each aliquot which was then placed on ice.
To physically map the location of the dihydrofolate reductase
gene, the sizes of the Bal 31 digestions were monitored by agarose gel
electrophoresis as described previously. The remainder of each sample
was then blunt end ligated and used to transform bacteria. Resultant
transformants were tested for sensitivity to TRM (2ug/ml) and digested
with the appropriate restriction endonuclease to ensure that Bal 31
digestion had taken place (see Results).
Yeast Transformation
Transformation of yeast cells with plasmid DNA followed a
modified procedure of Hinnen!! al., (1978). This method yielded
between 1 - 100 transformants with plasmids which require integration
into the yeast genome or 100 - 10,000 transformants with plasmids
which are capable of automonous replication per ug DNA.
To 80 ml of YPDP media approximately 107 yeast cells from an
overnight culture were added. This suspension was grown with shaking
at 30°C until the cell density reached 1 X 107 cells/ml. Cells were
harvested by centrifugation at SK for 5 min (Sorval SS34 rotor) and
the pellet was washed once with 1 M sorbitol. The cells were then
resuspended in 8 ml of 1 M sorbitol containing 1% glusulase and the
suspension was incubated with gentle shaking at 30°C for 30 - 90 min,
or until spheroplast formation was approximately 50% complete.
Spheroplasts were harvested by centrifugation at 2.5K for 5 min as
before. Cells were washed twice with 1 M sorbitol and then once with
20 ml STC (1 M sorbitol, 10 roM Tris HCl ph 7.5, 10 roM CaC1 2). The
pellet was then gently resuspended in 0.5 ml STC.
Plasmid DNA was added to the competent cells and after 15 min 10
volumes of PTC (20% PEG 4000, 10 mM Tris HCl pH 7.5, 10 roM CaC12) was
added. The suspension was incubated for 15 min after which cells were
harvested by low speed centrifugation (2.5K for 5 min), washed once in
STC and resuspended in 2 ml STC. 100 ul of competent cells was added
to 10 ml of regenerating agar (1 M sorbitol, 3% agar, 2% by volume YDP
media, 2% glucose, 0.67% yeast nitrogen base) at 48°C containing the
appropriate supplements to allow for the selection of transformants.
The suspension was then gently mixed to ensure a homogenous cell
distribution and immediately poured onto the appropriate SD agar
plates. Putative transformants were scored after incubation for 3 - 5
days at 30°C.
Radial Gradients
Approximately 106 exponential yeast cells were added to 20 ml
of YPDP top agar supplemented with 5 mg/ml sulfanilamide (Sulf). To
ensure a homogeneous cell distribution, the suspension was gently
vortexed and immediately poured onto a YPDP agar plate. 200 ug of
methotrexate (MTX) and 5 mg Sulf were added to a centre well to
establish a gradient of drug concentration which decreased toward the
periphery of the plate. After incubation at 30°C for 48 hrs, the
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induction of cytoplasmic petites was scored by overlaying the YPDP
agar plates with 0.1% 2,3,5 triphenyltetrazolum chloride (TTC) to
identify respiratory deficient mutants (jO-).
Methotrexate Sensitivity
Sensitivity of yeast cells to MTX was determined two ways:
1) radial gradients of antifolate drugs; 2) by culturing log phase
cells in MTX-Sulf supplemented YPD media.
Yeast cells were grown overnight in YPD media at 30°C to a cell
density of 2 - 4 X lOS/mI. Cells were harvested and inoculated into
fresh flasks containing YPD media supplemented with 5 mg/ml Sulf and
MTX at concentrations of 7.5, 15, 25, 50, 75, 100, 175, 250, and 500
ug/ml. The flasks were immediately placed into a rotary shaker water
bath and incubated for 12 hrs at 30°C. Samples were chilled on ice to
4°C and disrupted by brief sonication to disperse cell clumps. Cell
density was determined by counting using a Coulter counter (model ZF)
equipped with a 100 urn aperture. The suspensions containing 0 or 500
ug/ml MTX and 5 mg/ml Sulf were diluted, plated on YPD agar plates and
incubated at 30°C for 24 hrs.
Viable cell number was recorded and any putativejO - colonies
(white) were streaked onto YPG agar plates to confirm their)O-
phenotype. Cell morphology in the presence and absense of antifolate
drugs was analyzed microscopically.
Trimethoprim Sensitivity
Sensitivity of yeast ~ells to trimethoprim (2,4-diamino-5-
[3,4,5,-trimethoxy benzyl] pyrimidine) was determined in two ways;
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1) by spotting between 102 and 103 well washed cells onto SD plates
supplemented with the appropriate amino acids with and without
trimethoprim (TRM); and 2) by culturing log phase starved cells in
TRM-amino acid supplemented SD media. With either method it was
important to avoid contaminating the cell suspensions with traces of
yeast extract-peptone media as well as high cell concentrations since
both conditions diminish or abolish the sensitivity of 2 radiation
sensitive mutant strains (rad 6 and rad 18) to the antifolate TRM
(Lawrence and Christensen, 1979).
To obtain log phase starved cells, a modified Mayer and Goin
(1984) procedure was employed. Cells were preconditioned by
inoculating 2 - 4 X 10 4 cells/ml into amino acid supplemented SD media
and incubated at 30°C in a rotary shaker water bath overnight to
produce a midlog phase culture. These cells were harvested by low
speed centrifugation, washed 3 times with saline (0.8%), resuspended
in saline contained 0.1% glucose and incubated for a period of at
least 16 hrs at 30°C in a rotary shaker water bath to produce a midlog
phase starved culture. These measures were taken to deplete
intracellular folate pools and Cl metabolites that might interfere
with TRM sensitivity (Game et ~., 1975). Amino acid supplemented SD
media was used to dilute a stock TRM solution (2 mg/ml) to prepare
solutions containing 25, 50, 75, 100, 150, 200, 250, 300, and 500
ug/ml of the drug. The log phase starved cells were inoculated into
these solutions (15ml) to yield suspensions of 2 X 10 5 cells/ml.
These suspensions were immediately placed in a rotary shaker water
bath and incubated for 24 hrs at 30°C.
The samples were then chilled on ice and disrupted by brief
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sonication to disperse cell clumps. Cell density was determined by
counting using a Coulter counter as before. The suspensions which
contained 0 and 500 ug/ml TRM were diluted, plated on to amino acid
supplemented SD agar plates and incubated for 2 days. Viable cell
numbers were recorded and any putative p - colonies were streaked onto
YPG agar plates to confirm their ;0- phenotype.
Petite Induction by Ethidium Bromide
Exponential yeast cells were grown in the dark with gentle
shaking at 30°C in the presence of 30 ug/ml Ethidium Bromide (EtBr).
Aliquots were removed at 1 hr intervals, diluted and plated on YPDP
agar plates which were incubated at 30°C for 2 - 3 days. Viable cell
numbers were recorded and any white colonies were scored as putative
p - mutants. The /J - phenotype was confirmed as described previously.
M13 Cloning
After cloning the yeast dihydrofolate reductase DNA fragment in
to M13mp8 and M13mp19 a series of deletions were done to: 1) localize
the functional domain of~ 1; and 2) determine the primary base
sequence of DFR 1. These recombinant phage were characterized in
several ways; 1) spotting 10 ul of viral supernatant onto a lawn of
JM103 cells spread on L agar plates and on TRM (2ug/ml) supplemented
MIN agar plates; and 2) by agarose gel electrophoresis of single
stranded viral DNA (ssDNA).
Transfection of E. coli
To plate transfected cells 2 - 100 ng of recombinant phage DNA
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was added to 300 ul of competent cells in a 13 X 100 mm glass test-
tube and placed on ice for at least 40 min. The mixture was then heat
shocked for 2 min at 42°C immediately after which 10 ul of 100 mM
IPTG, 50 ul 2% Xgal, 0.2 ml fresh exponentially growing JMl03 cells
and 3 ml of soft B agar were added. These components were quickly
mixed and plated directly onto B plates which were incubated at 37°C
for 6 - 18 hrs. Turbid plaques and the colour reaction were seen
after approximately 4 and 6 hr respectively.
Preparation of Template DNA
Two ml of exponentially growing JM103 were placed into a sterile
50 ml plastic conical test-tube. A sterile toothpick was used to
"pick" a plaque and transfer the phage to the culture which was shaken
vigourously for 3 hr at 37°C. 0.1 ml of this culture was added to a
fresh sterile test-tube containing 1.0 ml of exponential JMl03 cells
and 9 ml of B media. After further incubation for 6 hr, as before,
cells were harvested by centrifugation at 2.7K for 15 min in an I.E.C.
clinical centrifuge (model Centra-7A).
Initial characterization of the recombinant phage was done by
withdrawing 10 ul of the supernatant and placing it into a 1.5 ml
microfuge tube containing 1 ul of 2% SDS and 3 ul of 0.1% bromophenol
blue solution. The sample was loaded onto a 0.7% agarose gel (in TBE
buffer), electrophoresed at 70 V for 5 hr and stained as described
previously.
The remainder of the supernatant was decanted in to a sterile
50 ml plastic test-tube which contained 900 ul of a 20% PEG solution
(in 3M NaCl). The mixure was left at room temperature for 15 min,
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then centrifuged for 30 min at 10K in an I.E.C. B20A centrifuge (870
rotor). Care was taken not to disturb the pellet while removing the
supernatant with a pasteur pipet after which the inside wall of the
test-tube was wiped with a Kimwipe. The pellet was resuspended in
0.4 ml of TES buffer and the solution transferred to a 1.5 ml micro-
fuge tube. 400 ul of phenol equilibrated with TES was added to the
microfuge tube, the solution was vortexed for 10 sec and centrifuged
at 12K for 1 min (Beckman Microfuge 12). After the aqueous phase was
removed the sample was ethanol precipitated (40 ul of 3 M sodium
acetate pH 6.0, 1 ml 95% ethanol) at -70°C for 30 min. The DNA was
recovered by centrifugation for 5 min as before and the pellet was
rinsed in 1 ml of 70% ethanol prechil1ed to -20°C. The supernatant
was carefully removed and the pellet dried under reduced pressure. 50
u1 of TE buffer was used to resuspend the DNA which was now ready for
sequencing.
Sequencing Procedure
The procedure used to sequence DFR 1 was that of Sanger ~ a1.,
(1977). For each sequencing reaction the phage M13 template was
prepared as described (Sanger et a1., 1980) and annealed to a
commercially available synthetic primer (Duckworth et a1., 1981) in a
1.5 ml microfuge tube. The annealings were performed by combining 4
ul of template DNA, 2 u1 of single-stranded primer, 1 u1 of 10 X
annealing buffer (10mM Tris HC1 pH 7.5, 10 roM NaC1) and 3 u1 H20. The
mixture was incubated in a tightly sealed microfuge tube at 55°C for
10 min in a 10 ml water bath after which the bath was allowed to
slowly return to room temperature.
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DNA synthesis reactions were carried out at room temperature in 4
1.5 ml microfuge tubes labelled A,C,G, and T. The primer-template
mixture was added to a microfuge tube which contained 40 uCi of
lyophilized o<32p dATP (New England Nuclear) and 2 ul of radioactively
labelled template mix was placed on the side wall of each tube.
Commercialy obtained A,C,G, and T reaction mixtures (P.L. Biochemical)
were dispensed in 3 ul aliquots to their respective tubes. To these
tubes 1 ul of ~ coli DNA polymerase 1 (large fragment) was added and
reactions were begun simultaneously after 2 sec microfugation. 1 ul
of Chase solution (P.L. Biochemicals) was placed on the side of each
tube and after 15 min incubation the tubes were centrifuged as before.
After 15 min incubation the reactions were stopped by addition of 3 ul
formamide stop solution (0.3% xylene cyanol FF, 0.3% bromophenol blue,
1 ml 100 mM EDTA pH 8.3, 9 ml deionized formamide).
The reaction tubes were placed into boiling water for 3 min
immediately prior to loading 3 ul of sample onto the polyacrylamide
gel. Electrophoresis of samples was carried out at 40 - 45 W in 1 X
TBE buffer. Routinely when non-gradient gels were used, samples were
loaded 3X at 90 - 120 min intervals, whereas samples were loaded only
once and run for 4 - 6 hr when buffer gradient gels were used.
Polyacrylamide Gel Electrophoresis
Two types of polyacrylamide gels were used during the course of
this study: 1) non-gradient gel; and 2) buffer gradient gel. In
either instance the gels were cast between 20 X 40 cm glass-plates
separated by 0.4 mm spacers. The glass plates were thoroughly washed
with a mild non-abrasive detergent, rinsed several times "ultra-pure"
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distilled water and then wiped with 90% ethanol.
Non-gradient Gel
For 60 ml of an 8% acrylamide solution the following were
thoroughly mixed; 25.2 g urea, 12 ml 40% acrylamide/bisacrylamide
(38:2), 6 mIlO X TBE buffer, 0.6 ml 10% ammonium persulfate,
distilled H20~ to a final volume of 60 mI. The solution was filtered
into a 125 ml flask and then placed on ice until the temperature of
the solution reached 15°C. Immediately prior to pouring the gel 30 ul
of TEMED was added and the solution swirled gently to ensure thorough
mixing. The gel was formed as previously described (Sanger and
Coulson, 1977) by pouring the gel solution down one side of the gel
mould. When the gel mould was completely filled the sharks-tooth comb
was inserted at the top of the gel. The gel was left flat on the
bench top until polymerization occurred.
Buffer Gradient Gel
Gradient gels used in the study were formed by a modified
procedure of Biggin!! ~., (1983). 35 ml of 0.5 X TBE gel mix
(25.2 g urea, 12 ml 40% acrylamide-bisacrylamide (38:2), 3 ml 10 X TBE
buffer, 0.2 ml 10% ammonium persulfate, 60 ul TEMED and distilled H20
to a final volume of 60 rol) was drawn into a 50 ml disposable syringe
and put on ice. A 25 ml graduated glass pipette was used to first
draw up 12 ml of the 0.5 X TBE gel mix followed by 12 ml of a 5.0 X
TBE gel mix (10.5 g urea,S ml 40% acrylamide-bisacrylamide (38:2),
6.25 rol 10 X TBE, 0.1 ml 10% ammonium persulfate, 2.5 g sucrose, 0.1
ml bromophenol blue, 30 ul TEMED and distilled H20 to 25 ml). Care
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of plastic wrap was placed over the gel.
was taken to minimize mixing of the two solutions while pipetting.
This resulted in a two-phase solution separated by a diffuse boundry
which was slightly mixed by allowing several air bubbles to run up the
pipette. The gradient was poured by running the gel mix down one side
of the gel mould until the mould was approximately half full. After
the gradient was poured, the gel mould was declined to a nearly
horizontal position approximately 1 inch above the bench top to arrest
the flow of the gel mix. The syringe containing the 0.5 X TBE mel
mixed was now used to finish pouring the gel. The bromophenol blue
edge gave a visual indication of how the buffer concentration gradient
formed. After the gel was cast the comb was inserted and the gel was
left to polymerize.
Gel Processing and Autogradiography
After electrophoresis was complete the gel was removed from the
sequencing apparatus. The glass plates were carefully separated to
prevent damage to the fragile gel. Wet areas were dried and a piece
Kodak~XR-5 film was used to
expose the gel for 12 - 18 hrs at -70°C.
The film was developed in Kodak~GBX developer for 5 min and
fixed in KodakQDGBX fixer. Primary nucleotide base sequence was
determined as described by Sanger and Coulson (1978).
49
Results
The yeast dihydrofo1ate reductase gene (tentatively named ~ 1)
was isolated previously from a J. Freisen yeast genomic library. The
selection technique exploited the differential sensitivities of
~. ~ dhfr and the yeast enzyme to the antifolate trimethoprim.
DNA/DNA hybridization studies confirmed that the 8.8 kbp yeast DNA
fragment isolated from the trimethoprim resistant clone was of yeast
origin (Barclay et a1., in prep.).
Prokaryotic dhfrs are strongly inhibited by trimethoprim, whereas
analogous eukaryotic enzymes show a much greater resistance to the
drug ~ vitro (Baccanari ~ ~., 1975). Preliminary experiments were
done to quantitate this difference in drug resistance between
wild-type bacterial strain (JF1754) and the same strain transformed
with the dhfr plasmid pDR420. Table 3 shows that TRM (2 ug/ml) in the
culture medium completely inhibited the host strain whereas bacterial
cells containing plasmid pDR420 grew substantially at this drug
concentration. Provision of higher amounts of TRM inhibited growth of
both cell types. To avoid the possibility of rearrangements in the
plasmid DNA sequence as a consequence of thymine depletion (Barclay
and Little, 1978), the drug concentration at which~ £2!! cells were
screened for a TRM-resistant phenotype was standardized at 2 ug/ml.
When exponential bacterial cells are grown in minimal medium
containing TRM but lacking exogenous Cl metabolites (Cohen and Barner,
1954) the bacteria enlarge without dividing, and die. This
"unbalanced growth" is due to a depletion of the intracellular folate
pools which results in a thymineless condition (Angehrn and Then,
1973). Figure 3 shows E. coli cells growing under normal and
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Table 3 Expression of the cloned yeast dihydrofolate reductase gene
in E. coli.
Survival (io)
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[TRM]
ug/ml
o
2
100
JF1754
100
<1.0
<1.0
JF1754/pDR420
100
89.0
2.3
Cells were grown under the conditions described in Methods.
Figure 3 Morphology of bacterial cells treated with trimethoprim.
Exponential cells of E. coli strain JM103 were grown in minimal
medium supplemented with~g/ml TRM, as described previously. After
8 h incubation the cells were examined by light microscopy and
photographed (see methods).
A) Exponential cells incubated in minimal media (X2000).
B) Exponential cells incubated in minimal media contained 2 ug/ml TRM
(X2000).
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folate-depleted conditions. Instead of the characteristic morphology
of balanced exponential growth, TRM treated cells became elongated and
filamentous. This is characteristic of E. coli cells in which DNA
synthesis has been inhibited.
As shown in Figure 4, the recombinant plasmid pDR420 contains 2
Sal 1 DNA fragments of 4.0 and 4.8 kbp. The smaller fragment
corresponds to the vector pACYC 184 and the larger fragment contains
the yeast insert and a portion of the tetracylene (Tc) gene. The 4.8
kbp DNA segment contained a Bam Hl site which when digested with the
enzyme generated fragments of 2.8 kbp and 2.0 kbp. The latter which
contained the DFR 1 gene was sub-cloned on a 1.8 kbp Bam Hl-Sal 1
fragment. It was this 1.8 kbp yeast DNA fragment which was used for
future constructions.
Plasmid Constructions.
In order to study the effects of the cloned yeast dhfr gene in
yeast the construction of several plasmids was required. The first
construction involved the directional cloning of the 1.8 kbp
Bam Hl-Sal 1 dhfr DNA fragment into the 5.5 kbp yeast integrating
vector YIP5. Initially, the recombinant plasmids were used to
transform E. coli and DFR 1 transformants were characterized by their
resistance to TRM. As a second control, the 3 TRM resistant colonies
were cured of their plasmid by growth under non-selective conditions
(Hsiao and Carbon, 1981) and it was determined that the TRM resistance
was plasmid encoded. Figure 5 shows that the restriction map of the 3
recombinant yeast dihydrofolate reductase plasmids pIUD 1, pIUD 2 and
pIUD 3 in lanes 4, 5 and 6 respectively were identical. In all cases
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Figure 4 Characterization of the plasmid pDR420.
1 ug of purified pDR420 DNA was digested with the restriction
endonucleases Bam H1 (lane 2), Sal 1 (lane 3) and Bam Hi and SaIl
(lane 4) as described previously. The DNA fragments were separated by
agarose gel electrophoresis (0.7%) in TBE buffer for 90 min at 70mV.
DNA bands were stained with EtBr, visualized under UV light and
photographed as described previously. ~DNA digested with Hind III was
used as standard (lane 1).
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Figure 5 Characterization of the DFR i-yeast integrating
plasmid pIUD 1.
The yeast dhfr fragment donor pDR420 and the shuttle vector YIP5 were
first digested with Bam Hi and then Sal 1, the fragments were ligated
and plasmids used to transform E. coli as described previously
(see Methods). Plasmid DNA from-3 TRM resistant transformants was
digested as above. DNA fragments were separated by agarose gel
electrophoresis (0.7%) and analyzed as before.
Lane 1 ~phage DNA digested with Hind III.
Lane 2 YIPS DNA digested with Bam H1 and Sal 1.
Lane 3 pDR420 DNA digested with Bam H1 and Sal 1.
Lane 4 pIUD1 DNA digested with Bam Hi and Sal 1.
Lane 5 pIUD2 DNA digested with Bam H1 and Sal 1.
Lane 6 PIUD3 DNA digested with Bam H1 and Sal 1.
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a 5.2 kbp fragment, which corresponded to the vector YIPS (lane 2) and
a 1.8 kbp fragment which corresponded to the dhfr Bam H1-Sa1 1 DNA
fragment of pDR420 (lane 3) were present.
The second construction involved the non-directional cloning of
the 2.0 kbp Bam Hi dhfr fragment into the 13.2 kbp autonomously
replicating shuttle vector pYF91. Resultant recombinant p1asmids were
screened in E. coli, as before, by their resistance to TRM as well as
the ability of the LEU 2 gene of pYF91 to complement the leu B mutant
E. coli strain JF1754 (Storms et a1., 1979). Of the 16 TRM resistant,
~+ p1asmids isolated (pDR501 to pDR516), 15 had the yeast
dihydrofo1ate reductase fragment in the same orientation as pIUD 1
(with respect to the ampicillin gene) and only pDR511 contained the
insert in the opposite orientation (Figure 6). This suggested that the
dhfr DNA fragment in addition to the structural gene for yeast
dihydrofolate reductase, also contained any necessary regulatory
elements which allowed the gene to express in bacteria.
For studies designed to physically map the yeast dihydrofolate
reductase gene and determine its primary nucleotide base sequence
using the Sanger e~ a1., (1977) dideoxy-chain termination method, two
recombinant phages (Messing and Vieira, 1982) containing DFR 1 were
constructed. Figure 7 shows the cloning strategy for these
constructions. They were characterized initially by their colourless
plaque phenotype on IPTG X-gal plates (see Methods) and secondly by
their resistance to TRM. Restriction map analysis confirmed that
these recombinant bacteriophage, M13mp8B13 and M13mp19B13 contained
the yeast dhfr fragment in the orientation shown. All attempts to
clone DFR 1 in the opposite orientation into the M13 viral vectors
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Figure 6 Schematic diagram of the construction of the chimeric
plasmids pIUD 1 and pDR509, 511.
The 1.8kbp dhfr DNA fragment from pDR420 was cloned into the yeast
integrating plasmid YIPS as described in the legend to Figure 5. A
TRM resistant, Ap+, URA 3 clone was characterized as described and
named pIUD 1.
Non-directional cloning of the yeast dhfr fragment from pDR420 into
the shuttle vector pYF91 was accomplished as described.
Characterization of 16 TRM resistant Ap+, LEU2 clones included
restriction map analysis to determine the orientation of the
dihydrofolate reductase fragment in the vector.
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Figure 7 Schematic diagram of the construction of the chimeric phage
M13mp8B13 and M13mp19B13.
The 2.0 kbp dhfr DNA fragment from pDR420 was cloned into the M13
vectors mp8 and mp19 as described previously. Recombinant phage were
used to transfect E. coli and putative M13-dhfr clones were
characterized by their-resistance to TRM in culture.
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were unsuccessful. Although the reason for this bias is unclear,
preferential insertion of cloned DNA fragments into M13 phage has been
observed previously (Messing ~ ~., 1981).
In order to study the expression of the cloned yeast
dihydrofolate reductase in mammalian systems, it was necessary to
construct a number of plasmids. Transduction of mammalian cells with
DNA is extremely inefficient without a selectable marker (Parker and
Stark, 1979). Thus, it is essential that the transducing vectors to
be used contain specific genes which allow transduced cells to be
grown preferentially. The two vectors used, pSV2-neo and pSV2-gpt
have been described previously (Mulligan and Berg, 1981). Figure 8
shows the cloning strategy and the resultant recombinant plasmids
pDN21 and pDG27.
The first construction (pDN21) was initially characterized in
E. coli by its Ap+, Neo+, and TRM+ phenotype, whereas pDG27 exhibited
an Ap+, TRM+ phenotype. Since it was not feasible to study the
effects of yeast dhfr expression in mammalian cells in our laboratory,
these plasmids were sent to Columbia University for further
characterization. Preliminary studies revealed that the cloned yeast
dihydrofolate reductase gene failed to complement the dhfr deficiency
of a f01- Chinese hamster cell line (L. Chasin, pers. comm.).
Table 4 summarizes the plasmids constructed during the course of
this study. In all cases the DFR 1 allele was present and the
plasmids were initially characterized in E. coli.
Localization of the Cloned DFR 1 Gene
The initial series of experiments designed to physically map
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Figure 8 Schematic diagram of the construction of the chimeric
plasmids pDN21 and pDG27.
The 2.0 kbp dhfr DNA fragment from M13mp8B13 was cloned in pSV-neo
and pSV-gpt as described previously. Recombinant plasmids were used
to transfect E. coli and putative dhfr DFR 1 transformants
were characterized as before.
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SV400ri
pSV2gpt
:J
B
SV400ri
Table 4 Plasmids used in this study.
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Plasmid
pDR420
pIUD 1
pDR509
pDR511
M13mp8B13
M13mp19B13
pDN21
pDG27
Characteristics
ori, ~+, DFR 1
ori, Ap+, URA3, DFR 1
ori, Ap+, 2u, LEU2, DFR 1
DFR 1
ori, ~+, ~+,
SV40 ori, DFR 1
ori, Ap+, gpt+,
SV40 ori, ~ 1
Source
G. Taylor
this study
this study
this study
this study
this study
the location of the cloned yeast dhfr gene utilized the M13-DFR 1
recombinant phage. Figure 9 shows the relative size of the various
M13mp8B13 and M13mp19B13 bacteriophage deletions which were
constructed. These clones were then tested for sensitivity to TRM
(2 ug/m1) by means of a spot test. Figure lOA shows that all 10 M13
derivatives formed plaques when spotted on a lawn of exponential JM103
cells growing on B agar media. However, when these same phage were
plated on MIN agar media supplemented with 2 ug/ml TRM only 3 clones,
M13mp8B13, M13mp19B13 and M13mp19B13~P grew.
These data suggested that the Bam H1-Pst 1 region of the 1.8 kbp
dhfr fragment was not necessary for yeast dihydrofolate reductase
expression in E. coli (Figure 11). Thus, the functional unit of
DFR 1 was localized to a 1.6 kbp fragment between Pst 1 and Sal 1
restriction cut sites. Before any further characterization of the
dhfr gene could be done it was necessary to construct a more accurate
restriction map of the fragment.
Figure 12 shows the DNA fragment sizes obtained when various
restriction endonucleases were used alone and in combination to digest
pIUD 1 DNA. These results are summarized in Figure 13. The
restriction map of pIUD 1 was constructed by combining the published
restriction map of YIPS (Scherer and Davis, 1979) and data obtained
from this experiment. Thus, one end of the yeast DNA fragment
necessary for expression in~ coli was localized to the 150 bp
Pst l-Eco Rl fragment. However, this procedure could not be used to
map the terminus of the ~ 1 gene in the other direction due to the
lack of suitable restriction endonuclease cut sites.
The ability of Bal 31 nuclease to digest duplex DNA was exploited
68
Figure 9 Characterization of the M13mp8B13 and M13mp19B13 deletions.
M13mp8B13 and M13mp19B13 DNA was digested with the restriction
endonucleases Hind III, Eco Rl and Pst 1 under conditions described
previously. The samples were religated and used to transfect the
bacterial strain JMl03. Single stranded DNA from appropriate phage
was isolated as before and subjected to agarose gel electrophoresis
(0.7%) at 70 mV for 5 hr.
A B
Lane 1 M13mp8 Lane 1 M13rnp19
Lane 1 M13mp8B13 Lane 2 M13mp19B13
Lane 3 M13mp8B13 I:::.. H Lane 3 M13mp19B13 I:::..H
Lane 4 M13mp8B13 I:::.. E Lane 4 M13mp19B13 I:::..E
Lane 5 M13mp8B13 I:::.. P Lane 5 M13mp19B13 I:::..P
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Figure 10 Trimethoprim sensitivity of the M13 based deletions
A lawn of cells of the bacterial strain JM103 (108) was spread on
a B plate (A) and on a Min plate (B) supplemented with 2 ug/ml TRM.
10 ul of each ssDNA isolated as described in the legend to Figure 9
was spotted on both plates and incubated for 24 - 72 hr at 37°C.
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1 mp8B13
2 mp8B13 1:::. H 1 13 mp8B13 a E
4 mp8B13 1:::. P
5 mp8 2 2
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1 mp19B13
2 mp19B13 1:::. H 4 43 mp19B13 1:::. E
4 mp19B13 1:::. P
5 mp19B13
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Figure 11 Schematic representation of the M13 constructions and
related trimethoprim sensitivity.
Data from Figures 9 and 10 were correlated to demonstrate the region
of the cloned dhfr DNA fragment necessary for the expression of yeast
dihydrofolate reductase in E. coli. ssDNA was isolated and
characterized as described in the legends to Figures 9 and 10.
Restriction Endonucleases
Bam H1 (B)
Eco Rl (E)
Hind III (H)
Pvu II (Pv)
Pst 1 (p)
Sal 1 (S)
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Figure 12 Characterization of the DFR 1 fragment
pIUD 1 DNA was digested with various restiction endonucleases as
described previously. The fragments were separated on a 2% agarose
gel at 50 mV for 3 hr and their sizes determined by comparison to
Hind III digested Aphage DNA.
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Lane DNA Enzyme(s)
1 pIUD 1 Bam Hi
2 pIUD 1 Bam Hi Sal 1
3 pIUD 1 Bam Hi Eco Rl
4 pIUD 1 Bam H1 Pst 1
5 pIUD 1 Bam Hi Hind III
6 pIUD 1 Hind III Pst 1
7 ~ phage Hind III
8 pIUD 1 Hind III Eco Rl
9 plUD 1 Sal 1
10 pIUD 1 Sal 1 Hind III
11 plUD 1 Sal 1 Pst 1
12 pIUD 1 Sal 1 Eco Rl
12 11 10 9 8 7 6 5 4 3 2 1
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Figure 13 Restriction map of the recombinant plasmid plUD 1
Data obtained from the restriction map analysis of DFR 1 and the
published restriction map of YIPS were combined to accurately map
plasmid pIUD 1 by standard techniques as described previously (see
Methods). Distances between restriction endonuclease sites given in
base pairs (bp).
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to locate the end of the DFR 1 functional unit within the 970 bp
HindIII-Sa1 1 fragment (Legerski !! a1., 1978). Nuclease Bal 31
contains both highly specific exonuclease and endodeoxyribonuclease
activity for double stranded DNA and potent endonuclease activity for
single stranded DNA or RNA. pIUD 1 DNA was first digested to
completion with Sal 1 restriction endonuclease. The DNA was then
treated with Bal 31 as described previously (see Methods). The
results are summarized in Figure 14.
In order to further localize the yeast dhfr gene, DNA from the
above experiment was ligated and used to transform ~ coli strain
JF1754. Transformants were characterized by their sensitivity to TRM.
Table 5 shows that the TRM resistant phenotype of plasmid pIUD 1
transformants was not lost until a deletion of approximately 1500 bp
of plasmid DNA occurred. This corresponds to a deletion of 750 bp
from the Sal 1 cut site on the Pst i-Sal 1 DNA fragment.
These data showed that the limit of the functional unit of the
DFR 1 gene was located approximately 220 to 370 bp from the Hind III
cut site on the Hind III-Sal 1 fragment. This suggested that the
smallest fragment on which DFR 1 could be cloned and still retain
dihydrofolate reductase activity in E. coli was between 630 and 930
bp.
Although 2 Fol- loci have been identified in ~ cerevisiae, the
location of the gene which in fact encodes yeast dhfr has remains
unknown. A plasmid which carries a yeast gene and no DNA replication
origin will integrate at its genomic locus by homologous recombination
(Hinnen et al., 1978). When the integration takes place, any
additional plasmid marker becomes tightly linked to the gene and its
Figure 14 Bal 31 nuclease treatment of plasmid pIUD 1.
DNA from pIUD 1 was first digested with Sal 1 and then treated with
Bal 31 nuclease for 30 sec intervals as described previously. Samples
were loaded on a 0.7% agarose gel and subjected to electrophoresis at
70 mV for 2 hr.
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Lane
1
2
3
4
5
6
7
8
9
10
11
12
Bal 31 Treatment
(sec)
o
30
60
90
120
150
Hind III digested ~phage DNA
180
210
240
270
300
121110 9 8 7 6 5 4 3 2 1
~ ~ ~ ~ ~ ~ ~ ~~ ...
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Table 5 Characterization of Bal 31 treated plasmids.
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Bal 31
(sec)
Average Plasmid
Size (bp)
Phenotype of
Transformants
(TRM)
Number Scored
0 7100 R 50/50
30 7000 R 37/37
60 6550 R 21/21
90 6200 R 43/43
120 5900 R 19/19
150 5600 S 33/33
180 5375 S 25/25
210 5175 S 18/18
240 5075 S 15/15
270 4975 S 13/13
300 4925 S 4/4
pIUD 1 DNA was digested to completion with Sal 1 restriction
endonuclease and treated with nuclease Bal 31 as described in Methods.
The DNA was ligated and used to transform bacterial strain JF1754.
Transformants were characterized by resistance to ampicillin (50ug/ml)
and trimethoprim (2ug/ml).
neighboring markers on the genome. The new linkage between markers can
then be examined by tetrad analysis after the integrant is mated with
a suitable strain.
In order to map the location of DFR 1, pIUD 1 DNA was used to
transform yeast strain M12B. Three transformants were sent to J. Game
(University of California at Berkeley) for the necessary matings and
tetrad analysis. All 3 of these integrants mapped to the same
location in the nuclear genome. Figure 15 shows that the cloned yeast
dhfr gene is closely linked to ~ 7 on chromosome 15 of ~.
cerevisiae (Game, pers. comm.).
In order to determine more accurately the location of the
structural gene encoding yeast dhfr and any attendant regulatory
regions, the DNA sequences of several segments of 1.6 kbp Pst i-Sal 1
fragment were determined by the method of Sanger et al. (1977). Figure
16 shows the sequencing strategy employed and the primary base
sequence obtained. Of particular interest was the stretch of 8 T
residues located 46 bp from the Eco Rl cut site which was preceded by
an opal stop codon (TGA) and a GC rich region.
To determine the direction of transcription of DFR 1, all 6
reading frames of this region were translated into the corresponding
amino acids. By comparison with the amino acid sequences of other
dihydrofo1ate reductases determined previously, a potential 3'
terminus of DFR 1 was identified on the EcoRl-Pst 1 fragment with a
"stop" codon 9 amino acids from the Eco Rl cut site (Figure 17).
Previously, it has been shown that the 4 dhfr sequences examined have
a phenylalanine residue at amino acid position 178 of Mus musculus
(Freisheim et al., 1977; Nunberg et a1., 1980; Smith and Calvo, 1980;
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Figure 15 Map location of DFR 1 on chromosome 15 of
s. cerevisiae ---
A plUD 1 integrant was used to map the location of the yeast
dihydrofolate reductase gene by standard techniques described
elsewhere (Fogel ~ a1., 1983).
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Figure 16 Partial nucleotide sequence of the yeast dihydrofolate
reductase "gene.
M13 derivatives were used as template DNA in the Sanger dideoxy-chain
termination sequencing method as described. Primary nucleotide base
sequences were confirmed by either sequencing the same fragment 3
times or by sequencing both strands of a particular fragment.
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Hind III
A A G C T T CAAGGAACGATTTTGTCCACGATAAAGAGAGATCAGATAGTCCAAAGTAATT
CATTGGCAAACCGCAATAATGAACCTAGAAAAGCAATTTTAACGGAGCATCTGGAAAGAACTCT
ACGTGATTGGGGGTGGCGAAGTCTCTATAGTCAAACTCTTCTCCATTACAGATCATTGGCTCAT
CACGAA
Eco Rl
G A A T T C ACTCTATACAATCGTAAATGAAACCTCTCCGCCCGTATATTTTTTTTAATAT
GTTAAATAGTGATAGAACTGATAAGCCTCATTTTCTTTTATTGGGCTCCAAGACGCGAACTGTT
Pst 1
CGTAGGGTAACCGTTTGAGACCTAAACGACCTTTCAGCCTCAC C T G C A G TATTTCTT
CAACAACGCCTGTCGGCTATGTTAAATAATAGCAATCGTTTGTGATCACCATTGTCGAATTTGA
CGCGCTTAAACCAAAAACCATTGTTTTGGCCTCGTTCCCTGCATTCAACAAAAGAGCAAGGTAT
GCCGTCAAACAGTCGTTAAAAGAGAACGGTTTATCAAACTACTCTTGTTTTGTACTTCTGCTGT
Bam Hi
CC G GAT C C
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FIGURE 17 Comparision of the 3' terminus of various dihydrofolate
reductase genes.
The amino acid sequence of the 3' terminus of S. cervisiae is
compared with those of E. coli, L. casei, M. mUSculus and
H. sapiens. The amino acids were aligned according to the
Structural equivalences described elsewhere (Volz et al., 1982).
Residues that are i"dentical with thoses in the yeast sequence are
enclosed in boxes.
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Iargl 89E. coli eys phe giu ile leu glu arg +++
L. casei arg phe gln lys gIn 1ys lys ala +++
s. cerevisiae glu phe thr leu tyr asn §j]~ +++
M. musculus lys phe glu val tyr glu lys Iys asp +++
H. sapiens lys phe giu val tyr giu 1ys asn asp +++
Chen et al., 1984). This was also found to be the case in the
potential amino acid sequence of ~. cerevisiae dhfr.
Effect of Antifolates in Yeast
When yeast cells are treated with antifolates, there is a
subsequent depletion of the tetrahydrofolate pools. This condition
creates an auxotrophic requirement for Cl metabolites. In yeast, these
folate depend nt end products are adenine, histidine, methionine and
dTMP. If yeast cells are starved for dTMP alone, by provision of
adenine, histidine and methionine in the growth medium, there is a
progressive shift in the distribution of the population within the
cell cycle (Laskowski and Lehmann-Brauns, 1973). After approximately 6
hr incubation in YPD broth medium (which contains adenine, histidine
and methionine, but not dTMP) supplemented with 200 ug/ml MTX and 5
mg/ml Sulf, yeast cell populations consisted entirely of parent cells
with buds of equal size attached (Figure 18). This morphology is
characteristic of cells in which DNA synthesis has been inhibited
either by genetic lesion (Hartwell, 1974) or in cultures treated with
hydroxyurea (Slater, 1974).
As a preliminary experiment to determine the effect of DFR 1 on a
multicopy plasmid (pDR509) on dihydrofolate reductase inhibition in
wild-type and 2 mutant yeast strains, a radial gradient technique was
employed. In this study, the procedure was used qualitatively to
assess the effects of a range of MTX concentrations on a single ,agar
plate. A lawn of cells was spread on a YPD agar plate and 1 mg MTX
and 5 mg Sulf was added to a center well. This establishes a gradient
of' MTX concentration which decreases towards the periphery of the
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Figure 18 Morphology of yeast cells treated with methotrexate.
Exponential cells of yeast strain AH 2 were harvested by
centrifugation and resuspended in YPD media. Cells were stressed for
folates by the addition of 200 ug/ml MTX and 5 mg/ml Sulf. After 6
hr incubation at 30°C the cells were examined under a light microscope
and photographed (see Methods).
A) Exponential cells incubated in YPD media.
B) Exponetial cells incubated in YPD media supplemented with 200
ug/ml MTX and 5 mg/ml Sulf.
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plate. As shown in Figures 19a, 20a and 21c, after 24 - 72 hr
incubation yeast cells exhibited a zone of growth inhibition around
the well. Growth occurred in this area of the plate when in yeast
strains transformed with the multi-copy plasmid pDR 509 (Figure 19c,
20b, 21b). A pIUD 1 integrant in a rad 18 host showed an intermediate
zone of growth inhibition (Figure 21a). Wild-type yeast strain AH2
transformed with the shuttle vector pYF91 also exhibited a zone of
growth inhibition around the well similar to that of the host (Figure
19b). These data clearly demonstrate that the cloned yeast dhfr gene
is expressed in yeast.
Although, the copy number of pDR509 is not known, Storms ~ Al.,
(1979), have reported that the shuttle vector pYF91 is maintained at
approximately 8 to 10 copies per cell. If this is also true for DFR 1
_ pYF91 recombinant plasmids, these data suggest that the protection
afforded to yeast cells to growth inhibition by MTX is a result of a
gene dosage effect.
This conclusion is supported by the inhibition studies of the
yeast strains grown in culture at various MTX concentrations. In all
3 yeast strains, a similar inhibition of growth was observed in
response to this antifolate (Figures 22,23,24). However, rad 6 cells
seemed to be slightly more sensitive than wild type or rad 18 cells at
low levels of the drug (~25ug/ml). Consistent with the previous
results from plate tests, yeast strains containing plasmid pDR509 were
more resistant to MTX than the pIUD 1 integrant in culture.
In addition to the growth inhibition observed in cells treated
with MTX, there was also an absolute decrease in the survival of the
3 yeast strains (Table 6). Cells transformed with the vector pYF91,
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Figure 19 Inhibition of wild-type cell growth by MTX
Approximately 106 cells of strain AH 2 were added to 10 ml of ypn
top agar and immediately plated onto a ypn plate. To the center well
1 mg MTX and 5 mg Sulf were added. After incubation at 30°C for 24 -
28 hr the plate was overlayed with TTC as described previously (see
Methods).
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Strain
AH 2/pYF91
AH 2/pDRS09
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Figure 20 Inhibition of rad 6 cell growth by MTX
Approximately 10 6 cells of strain LLP2730-1A were plated onto a
YPD plate as described in the legend to Figure 20. 1 mg MTX and 5 mg
Sulf were added to the center well and after 72 hr incubation at 30°C
the plate was overlayed with TTC as described previously.
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Plate
A
B
Strain
LP2730-1A
LP2730-1A/pDR509

Figure 21 Inhibition of rad 18 cell growth by MTX
Approximately 106 cells of strain LP2729-4B were plated onto a
YPD plate as before. 1 mg MTX and 5 mg Sulf were added to the center
well and after 48 - 72 hr incubation at 30°C the plate was overlayed
with TTC as described previously.
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LP2729-4B/pIUD 1
LP2729-4B/pDR509
LP2729-4B
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Figure 22 Inhibition of growth by methotrexate of a wild type-yeast
strain.
Exponential cells were harvested by centrifugation and resuspended in
YPD medium supplemented with various MTX cconcentrations and 5 mg/rnl
Sulf. Aliquots were taken after 8 hr incubation and cell density was
determined by counting in a Coulter counter (see Methods).
o Wild-type yeast strain
• Wild type yeast strain transformed with the multi-copy DFR!
plasmid pDR509
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Figure 23 Inhibition of growth by methotrexate of a rad 6 mutant
yeast strain.
Exponential cells were harvested by centrifugation and resuspended in
supplemented YPD medium as before. Aliquots were taken after 8 hr
incubation and cell density was determined as described previously.
~ rad 6 yeast strain
• rad 6 yeast strain transformed with the multi-copy DFR 1
plasmid pDR509
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Figure 24 Inhibition of growth by methotrexate of a rad 18 mutant
yeast strain.
Exponential cells were harvested by centrifugation and resuspended in
supplemented YPD medium as before. Aliquots were taken after 8 hr
incubation and cell density was determined as described previously.
o rad 18 yeast strain
+ rad 18 yeast strain transformed .with the single copy
DFR 1 plasmid pIUD 1
• rad 18 yeast strain transformed with the multi-copy
DFR 1 plasmid pDR509
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Table 6 Survival of various yeast strains during folate depletion.
Survival (10)
106
wt
wt + pYF91
wt + pDR509
rad 6
rad 6 + pDR509
rad 18
rad 18 + pIUD 1
rad 18 + pDR509
No Drug
97.2
98.8
98.6
87.0
87.9
87.6
87.2
87.1
[MTX]
(500 ug/ml)
1.3
2.9
56.1
0.9
11.0
3.3
9.3
12.8
[TRM]
(500 ug/ml)
70.4
70.1
83.4
0.2
0.3
7.9
8.1
7.5
Cells were cultured and plated under the conditions outlined in
Methods. Cell viability was determined using a Coulter counter
(model ZF). .
exhibited similar cell killing as the host without the plasmid. Cell
viability in strains containing the DFR 1 plasmid pDRS09 was greatly
increased when grown at the same drug concentration (SOOug/ml). A
characteristic of yeast cell populations containing wild-type genes on
plasmids which complement analogous mutant alleles on the chromosome
is phenotypic instability. The plasmid loss in growing yeast
populations occurs even when the cells are cultured under selective
conditions (Struhl ~ al., 1979). When this is taken into account,
it is likely that complete protection against cell death is
conferred upon cells which have retained the DFR 1 plasmid.
As mentioned previously, wild-type yeast are refractory to the
growth inhibition by trimethoprim. The results of preliminary
experiments showed that yeast can grow normally in the presence of
TRM up to concentrations of 1.5 mg/rnl. However, wild-type cell
populations can be sensitized by preincubation of the cells in saline
overnight by a procedure described by Mayer and Goin, (1984) which
depletes the nutrient reserves of the cells. There exist 2 mutants,
rad6 and rad 18, which have been shown to be sensitive to this folate
antagonist (Game et al., 1975). Since TRM is thought to be a specific
inhibitor of dihydrofolate reductase, it seemed likely that these
cells transformed with the DFR 1 gene might be much less sensitive to
te effects of the drug.
Consistent with findings published previously, rad6 and rad 18
cell populations were more sensitive to growth inhibition by TRM than
the wild-type strain at all drug concentrations tested (Figures 25, 26
and 27). The presence of DFR 1 on a multicopy plasmid had no effect
on cell growth in the TRM treated populations. Moreover, no increase
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Figure 25 Inhibition of growth by trimethoprim of a wild-type yeast
strain.
Exponential cells were starved for folates as described previously and
resuspended in MIN medium supplemented with various TRM
concentrations. Aliquots were taken after 24 hhr incubation and cell
density was determined by counting (see Methods).
o Wild-type yeast strains
• Wild type yeast strains containing the multiple copy DFR 1
plasmid pDR509
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Figure 26 Inhibition of growth by trimethoprim of a rad 6 mutant
yeast strain
Exponential cells were starved for folates and resuspended in various
TRM concentrations as before. Aliquots were taken after 24 hr
incubation and cell density was determined as described previously.
~ rad 6 mutant yeast strain
• rad 6 mutant yeast strain containing the multi-copy DFR 1
plasmid pDRS09
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Figure 27 Inhibition of growth by trimethoprim of a rad 18 mutant
yeast strain.
Exponential cells were starved for folates and resuspended in various
TRM concentrations as described previously. Aliquots were taken after
24 hr incubation and cell density was determined as before.
Orad 18 mutant yeast strain
+ rad 18 mutant yeast strain containing the single copy
DFR 1 plasmid pIUD 1
• rad 18 mutant yeast strain containing the multi-copy
DFR 1 plasmid pDR509
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in cell viability was observed in drug treated strains harboring the
cloned yeast dhfr gene compared to that of the host (Table 6). These
results are somewhat surprising since the ability of increased copies
of the gene to enhance resistance to TRM in host cells was the basis
of the original selection procedure used to isolate the yeast dhfr
gene in~. coli. In addition, the results obtained in similar
experiments using the dhfr inhibitor MTX, are in direct contrast.
As mentioned previously, in addition to cell killing, inhibition
of C1 metabolism by folic acid analogues such as MTX results in the
formation of respiratory deficient mutants in yeast (Wintersberger and
Hirsch, 1973). Cytoplasmic petites are known to arise as a consequence
of a loss of a portion or all of the mitochondrial genome (Bernardi,
1978). Since yeast is a facultative anerobe, lesions occurring in
either the nuclear or mitochondrial genome can be readily
distinguished. It was thought that the sensitivity of the
mitochondrial genome to folate depletion might be a very sensitive
index of the effects of the dihydrofo1ate reductase gene expression
under folate deprived conditions.
The rate of spontaneous petite induction for the 3 yeast strains
is shown in Table 7. Consistent with previous findings, a high
frequency of petites were induced in wild-type and rad 18 cell
populations cultured in the presence of MTX (Wintersberger and Hirsch,
1973). In sharp contrast to these results, the rad 6 mutant showed a
very low level of spontaneous petite induction (0 of approximately
2000 clones examined). Furthermore, MTX apparently failed to induce
petities in this strain (0 of approximately 150 clones examined). One
interpretation of this finding is that rad 6 is an obligate grande.
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Table 7 Frequency of cytoplasmic petites induced by antifolate drugs.
Peti tes (io)
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wt
wt + pYF91
wt + pDR509
rad 6
rad 6 + pDR509
rad 18
rad 18 + pIUD 1
rad 18 + pDR509
No Drug
1.4
1.0
1.2
o
o
1.2
1.0
1.1
[MTX]
500 ug/ml
86.8
86.5
90.1
o
o
72.4
67.8
68.8
[TRM]
500 ug/ml
1.1
0.9
0.8
o
o
1.0
1.4
1.3
Cells were cultured and plated under the conditions given in the
legend to Figure 22. Respiratory competence of clones was determined
as described in Methods.
To test this hypothesis yeast strains were treated with ethidium-
bromide, a drug which is known to induce petites very strongly in
yeast (Fukunaga and Yielding, 1981). This drug induced p- in rad 6
cells at a level approximately 50% of those exhibited in~ 18 and
wild 2type cell populations (Table 8). Thus, even though rad 6 is not
an obligate grande, it seems to be very refractory to mitochondrial
damage by chemical means.
Although, the rad 6 strain could not be used to determine the
effects on the induction of respiratory deficient mutants by
antifolates, the rad 18 and wild-type cell populations were suitable
for these types of studies. Surprisingly, the presence of DFR 1 on a
multicopy plasmid did not affect the viability of any of the 3 strains
tested (Table 6). Furthermore, TRM did not induce the formation of
respiratory mutants in these yeast cell populations (Table 7).
Taken as a whole, these data suggest that yeast cells cultured in
the presence of high concentrations of TRM do not exhibit the
characteristic effects of antifolates in yeast. One interpretation of
these data is that the dihydrofolate reductase enzyme may not be the
target of trimethoprim in yeast.
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Table 8 Induction of cytoplasmic petites by EtBr.
Peti tes (/0)
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Time (hrs)
Control
1
2
3
4
wild-type
2
33
45
79
95
rad 6
o
17
34
50
53
rad 18
2
31
41
70
90
Cells were grown in media supplemented with 10 ug/ml EtBr and plated
as described in Methods. Respiratory competence of clones was
determined as mentioned previously.
Discussion
The yeast dihydrofolate reductase gene (~ 1) is present on a
8.8 kbp Bam H1 DNA fragment in the yeast nuclear genome ( Barclay et
a1., in. prep.). During the course of this study a similar fragment
containing the dhfr gene was cloned in a by selection of trimethoprim
resistance in E. coli (Nath and Baptist, 1984).
As yeast is intermediate in biological complexity relative to
bacteria and mammalian cells, studies of yeast dhfr gene expression
may serve as a model system for extrapolation to higher cells. To
date, of the yeast genes which have been characterized, most do not
contain intervening sequences (Holland and Holland, 1979; Montgomery
et al., 1980). Expression of yeast dhfr in ~ coli may suggest that
this gene unlike corresponding eukaryotic dhfrs of mouse and human
cell lines lacks intervening sequences to any great extent (Nunberg
et al., 1980; Chen!! al., 1984). Therefore, it was possible to
isolate DFR 1 like many other yeast genes from a genomic DNA library.
An obvious advantage of this procedure as compared to cloning
complementary DNA from messenger RNA, is that the DNA segment isolated
from the genome may not be limited to just the structural sequence.
Thus, it was hoped that along with the gene encoding yeast dhfr, any
attendant regulatory regions would also be isolated.
The expression of DFR 1 is independent of its orientation on the
shuttle vector pYF91. This suggests that the expression of yeast
dihydrofolate reductase does not depend upon any regulatory sequences
resident on the vector. Thus, the DNA insert may contain yeast
regulatory regions in addition to the structural gene encoding dhfr.
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In almost all cases, where the dihydrofolate reductase gene
product has been characterized, it consists of a single polypeptide of
about 21,000 molecular weight (Benkovic, 1980). A protein of this
size corresponds approximately to a DNA coding region of 5 to 6
hundred base pairs. Therefore, the 1.8 kbp DNA fragment necessary for
yeast dhfr expression in ~ coli, is large enough to accommodate the
structural gene and putative regulatory regions.
One of the primary aims of this study was to physically map the
location of the DFR 1 gene. A useful finding was that the DNA
fragment when cloned into M13 bacteriophage, conferred resistance to
host cells. This is an interesting system in which a eukaryotic gene
on a viral vector is expressed in a prokaryotic host. Expression of
drug resistance in the M13 system was convenient to characterize
deletions from the 1.8 kbp yeast DNA fragment in both M13mp8B13 and
M13mp19B13. The results of these deletion experiments suggested that
the Bam Hi - Pst 1 region of the yeast DNA segment was not necessary
for yeast dhfr expression in bacteria. Thus, the functional unit of
DFR 1 was initially localized to the 1.6 kbp DNA fragment between the
Pst 1 and SaIl restriction sites.
The ability of nuclease Bal 31 to digest duplex DNA (Legerski
et al., 1978) was exploited to create a series of deletions from the
Sail restriction site of the DFR 1 fragment in plasmid pIUD 1. Bal 31
treated DNA was used to transform E. coli and the resultant ampicillin
resistant clones were screened for sensitivity to trimethoprim.
Results of these experiments limited the functional unit of DFR 1 to a
region approximately 220 to 370 bp from the Hind III cut site. These
data suggested that a 630 to 930 bp DNA fragment was sufficient for
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expression of yeast dhfr in~. coli. This size is consistent with
dhfr genes from other organisms (for a review see Burchall, 1983).
This is a reasonable estimate for the size of the DFR 1 functional
unit, since it is large enough to contain a DNA coding region of
approximately 550 bp as well as attendent regulatory sequences.
A second aim of this study was to begin to determine the primary
nucleotide sequence of DFR 1. DNA sequence analysis of the Bam Hl -
Eco Rl segment of the 1.8 kbp yeast DNA fragment containing the dhfr
gene revealed a potential 3' terminus located 27 nucleotides from the
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Eco Rl cut site. Previously, it was shown that the dhfr amino acid
sequences of ~ col i, L. casei, M. musculus and H. sapiens have in
common a phenylalanine residue at position 178 of the mouse sequence
(Freisheim et a1., 1977; Nunberg et a1., 1980; Smith and Calvo, 1980;
Chen ~ a1., 1984). This was also found to be the case in S.
cerevisiae.
Another potential regulatory point 3' to the structural gene
is the po1yadenylation site of mRNAs whose fate is to be ultimately
translated in the cytoplasm. It has been reported that nearly all
yeast mRNA's become polyadeny1ated (Hereford and Rosbash, 1977). In
SV40, the sequence AAUAAA is necessary for polyadenylation (Fitzgerald
and Shenk, 1981). In the chick ovalbumin system, sequences both 5'
and 3' to AAUAAA have also been shown to be essential in poly A site
selection (Benoist et al., 1980). Conversely, Tosi et a1., (1981)
-- --
have suggested that po1yadenylation of the mouse amylase transcipt
does not occur at the AAUAAA sequences located in the 3' region of the
gene.
Zaret and Sherman, (1982) have reported that the sequence AAUAAA
may be the poly (A) sequence in yeast. However, these authors point
out that since the 3' non-translated regions of most yeast genes
sequenced to date are A - T rich, it is not surprising to find
sequences related to AAUAAA which occur by chance alone.
Interestingly, a potential poly (A) sequence was identified in the
Eco Rl - Bam Hl DNA fragment. The DFR 1 gene of yeast 'contains an
AAATAA sequence 174 bp 3' to the stop codon which is closely related
to the putative poly (A) recognition site reported by Zaret and
Sherman (1982).
In addition, the potential termination sequences TAGT or TATGT
which have been identified in the 3' non-translated regions of most
yeast genes sequenced (for a review see Andreadis et al., 1984;
Mantsala and Zalkin, 1984; Zaret and Sherman, 1982) are also found in
this region. This sequence usually occurs in yeast 10 - 40 bp before
the first known polyadenylation site. However, there are exceptions
such as, certain ribosomal proteins in which the sequence is located
after the poly (A) site (Zaret and Sherman, 1982). In addition to
these putative termination signals, an upstream sequence, TAG and a
downstream sequence, TTT, have been often identified in the 3'
non-translated regions of most sequenced yeast genes (Andreadis et
al., 1984; Mantsala and Zalkin, 1984; Zaret and Sherman, 1982). For
these reasons, in has been suggested that this triparte sequence:
[stop ••• l - 140 (T rich) •.• TAG ••• TAGT or TATGT •• (AT rich) ••. TTT]
may have a role in transcription termination and/or polyadenylation in
some yeast genes.
Three TATGT or TAGT sequences can be identified in the 3'
non-translated region of DFR 1. In all cases these sequences were
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located prior to the putative polyadenylation site AAATAA.
Interesting, a triparite structure which was in perfect correspondence
with those mentioned before was identified 98 bp from the stop codon.
As expected the TAG sequence was preceded by a T rich region (37%).
Moreover, the TATGT sequence was followed by an A - T rich region
and the TTT component of the consensus termination/poly (A) sequence.
These data suggest that the putative transcription termination/
polyadenylation sequences of yeast DFR 1 are similar to those
identified in other yeast genes.
The molecular mechanism of mRNA transcription termination in
yeast is not well characterized. Since yeast is intermediate in
biological complexity between bacteria and higher eukaryotes, it is
not unreasonable that yeast could follow either a prokaryotic or a
eukaryotic termination system. If yeast follows the mammalian
pattern, the presence of several tentative poly (A) sites in DFR 1 may
suggest multiple sites of transcription termination. This has been
shown to be the case in mouse dhfr, where there are at least 4 mRNA's
of differing sizes (Setzer et~., 1980). Setzer attributes this size
heterogeneity of the mRNA transcripts to the use of different poly (A)
sites 3' to the mouse structural dhfr gene.
Although, the DNA sequences which function in transcription
termination in eukaryotes are not well understood, the analogous
structures in bacteria have been well characterized. As yeast is a
relatively simple eukaryote, it is conceivable that transcription
termination could follow the bacterial example. It is interesting
to note that DFR 1 contained a GC rich region followed by a stretch of
8 T residues. These are located 46 bp 3' to the opal stop codon and
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are reminiscent of transcription termination in bacteria. Analogous
sequences have been identified in the corresponding region of the
~ 2 yeast gene (Andreadis ~ a1., 1984). In some bacteria,
transcription terminators consist of a GC rich region of dyad
symmetry followed by 6 - 8 T residues (Rosenberg and Court, 1979).
However, no such symmetry is apparent in the GC rich regions 3' to
either yeast gene.
At present, approximately 20 dihydrofolate reductases of
bacterial and mammalian origin have been sequenced (Appendix 1). In
general, bacterial dhfr's contain about 160 amino acids whereas avian
and mammalian forms have approximately 25 additional residues, which
are linked in a single chain (for a review see Burchall, 1983). In
contrast, R plasmid R67 encoded dihydrofolate reductase consists of 4
identical subunits (Stone and Smith, 1979). The dhfrs identified from
mammalian sources show great similarity. For example, the amino acid
sequences of mouse and human dhfr differ in only 21 of the 186
residues (Chang!! ~., 1979; Chen et a1., 1984). However, plasmid
encoded dihydrofolate reductases show very little amino acid
conservation.
Bacterial dihydrofolate reductases are not as homogenous as
mammalian enzymes, however, there is some evidence for a common
ancestry (Burchall, 1983). Approximately 30 of the 160 amino acids of
bacterial dhfr's are identical. Although the bacterial enzymes
exhibit certain common characteristics (ie. single polypeptide of
160 amino acids), they can be distinguished from each other by the
proper selection of inhibitors. For instance, ~ £2li dhfr is much
less sensitive to inhibition by the folate antagonist methotrexate
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than is the analogous Streptococcus faecium enzyme (Gleisner ~ al.,
1974). Conversley mammalian dihydrofolate reductases exhibit
very similar inhibition kinetics in response to methotrexate (Chen
Eal., 1984).
A small number of amino acids are common to all of the bacterial
and mammalian dhfr enzymes sequenced to date. Hitchings and Roth
(1980) have reported that the 20 conserved residues (excluding R67 and
R388 dhfrs which have only 16 of the common amino acids) have some
essential role in the catalytic activity and regulation of the enzyme.
Fling and Richards (1983) have suggested that some of these residues
are necessary for inhibitor and cofactor, bindings.
A third aim of this study was to subclone DFR 1 into various
shuttle vectors to be used in experiments on the expression of the
yeast dhfr gene in a mutant Chinese hamster cell line. In addition,
it was necessary to clone the yeast dhfr gene into the integrating
vector YIPS to determine the map location of this gene.
In order to study the expression of the cloned yeast dihydrofolate
reductase gene in a heterologous eukaryotic sustem, DFR 1 was cloned
into the mammalian transducing vector pSV-neo (Mulligan and Berg,
1981). This plasmid was sent to L. Chasin (Columbia University) for
subsequent experiments in a Chinese hamster cell line. Preliminary
experiments revealed that although plasmid pDN 21, which contained
DFR 1 and a drug marker (G418) conferred G418 resistance to host
cells, the yeast dhfr gene failed to complement the dhfr deficiency of
a fol- Chinese hamster cell line (L. Chasin, pers. comm.). One
interpretation of these results may be that in this heterologous
system, the yeast regulatory sequences are not recognized by the
124
mammalian cells, thus there is no expression of the dhfr enzyme.
Although, an extensive genetic map of the 17 chromosomes of S.
cerevisiae is available, the location of DFR 1 remains unknown
(Mortimer and Schild, 1980). This may be due in part to the lack of a
mutant deficient in dihydrofolate reductase, which would facilitate
the mapping of the gene by classical mapping techniques. However,
with the advent of recombinant DNA technology and more specifically,
gene cloning, this problem has been overcome.
In the absence of a mutant strain, it is now possible to map a
cloned yeast gene by the construction of plasmids containing other
scoreable markers tightly linked to the gene of interest ( Struhl,
1983). The plasmid is then integrated into the host strain and
the selectable marker can then be mapped by standard classical genetic
techniques. By choosing a host which has a deletion through the
chromosomal region containing the selected gene, virtually all
transformants contain the integration at the genomic locus of
interest.
In order to map the location of DFR 1, plasmid pIUD 1 (which
contains URA 3) was used to transform a yeast strain in which the
URA 3 gene had been deleted from the genome (M12B). This ensures that
there is no URA 3 homology between plasmid and host. Thus, most
recombination will occur at the genomic location of DFR 1. Three
pIUD 1 integrants were sent to J. Game (University of California
at Berkeley), who mapped the yeast dihydrofolate reductase gene on
chromosome XV closely linked to Met 7 (Game, pers. comm.).
Previously, 2 other mutants of genes in the folate biosynthetic
pathway were isolated (Little and Haynes, 1979). Although these genes
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have not been further characterized (ie. gene product identified),
they have been mapped (Mortimer and Schild, 1980). On the basis of
their requirements for C1 metabolites, Jones and Fink (1982),
tentatively identified tmp 2 as a mutant allele of dhfr. It is now
known that the tmp 2 mutants consist of 2 complementation groups,
foIl and fol 2. The map locations of these genes have been
identified and since DFR 1 maps to a different chromosome, it is
unlikely that TMP 2 encodes the structural gene for yeast
dihydrofolate reductase.
Although many of the details of the control and regulation of
folate biosynthesis in yeast are not known, depletion of
tetrahydrofolate pools has been shown to induce thymineless death
(Barclay and Little, 1978). Other effects of thimidylate deprivation
in yeast include: 1) induction off' - and mitochondrial point
mutations; 2) errosion of the mitochondrial genome; and 3) DNA strand
breaks (for a review see Barclay~~, 1982). Since antifolates have
been shown to induce thymineless conditions (Wintersberger and Hirsch,
1973), it was of interest to determine if the presence of DFR 1 on a
multicopy plasmid would afford host cells protection against thy-
associated lethality and mitochondrial damage.
It was convenient to use MTX as an index of expression of yeast
dhfr gene since this drug is known to inhibit the activity of
dihydrofolate reductase. In all three yeast strains tested, a similar
inhibition of growth was observed in response to this antifolate.
However, these strains containing the yeast dhfr gene on a multicopy
plasmid exhibited an enhanced resistance to MTX at the same drug
concentrations. This cleary demonstrates that DFR 1 is expressed in
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yeast. Furthermore, the intermediate resistance to MTX afforded to
the DFR 1 integrant suggests that the level of antifolate resistance
is gene dosage dependant.
As mentioned previously, the inhibition of folate biosynthesis by
folate antagonists results in the induction of jO- .. Thus, another
index of yeast dhfr expression was available to study the effects of
folate deprivation on DFR 1. Consistent with previous findings, a
high frequency of petites were induced in wild-type and rad 18 cell
populations treated with MTX. One surprising result was that the
presence of DFR 1 had no effect on;o-formation in either of these
strains. Another curious finding was the lack of petite formation in
rad 6 cells, both spontaneously and upon exposure to the antifolate.
One possible interpretation of these data may be that there exist two
pools of folate in this organism.
If one ascribes the induction ofjO-in cells treated with MTX to
depletion of folates, due to an inhibition of dhfr, a critical
question is raised, "Do mitochondria make their own folates or are
they imported from the cytoplasm?". If there exists a folate pool
common to both mitochondria and the cytoplasm, it is speculated that
the presence of DFR 1 on a multicopy plasmid would provide enough dhfr
for both systems. Thus, there should be a decrease in the frequency
of MTX induced;o- •
In contrast the results presented here suggest that available
nuclear folate pools may not be available to the mitochondria. These
data support the notion put forth by Luzzati (1975), that there exist
2 forms of same folate interconversion enzymes: 1) an enzymatic
activity isolated to the cytoplasm; and 2) an analogous enzyme
associated with the mitochondrian. If Luzzati is correct, there is a
compartmentalization of fo1ates and excess dhfr in the cytoplasm will
have no effect on mitochondrial folate pools.
One interesting question raised by these speculations is, "Would
the importation of "cytoplasmic" folates into the mitochondria have an
effect on the formation of cytoplasmic petites?". These experiments
may be possible in the near future, in light of the recent finding
that a yeast mitochondrial precursor was sufficient to direct a mouse
cytoplasmic enzyme into the yeast mitochondrial matrix (Hurt et ~,
1984)
In contrast to the inhibitory effects of MTX on yeast cell growth
it has been shown that wild-type yeast are refractory to the
inhibition of trimethoprim up to concentrations of 1.5 mg Iml. The
magnitude of this resistance is realized when it is remembered that
the growth of ~~ is strongly inhibited by 2 uglm1 of this drug.
However, there exist several radiation sensitive mutants of .§..
~erevisiae which exhibit a sensitivity to trimethoprim. The Rad 6 and
Rad 18 genes of~. cerevisiae are 2 of at least 9 genes involved in
the error-prone dark repair system of UV-induced pyrimidine dimers
(for a review see Game, 1983). Although the precise function of the
~ 6 gene product in yeast is unknown, it has been shown that
mutagenesis by physical or chemical means requires a functional Rad 6
gene (Prakash, 1974; Lawrence and Christensen, 1976).
Since there is no a priori reason to expect a correlation between
the inhibition tetrahydrofolate biosynthesis and radiation sensitivity
it remains puzzling that mutant alleles of these loci in addition to
abolishing a mode of DNA repair, also confer sensitivity to the folate
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antagonist trimethoprim.
In light of these facts it is conceivable that, rad 6 or rad 18
are allelic to DFR 1. However, comparision of the restriction maps of
DFR 1 and RAD 6 suggested that these are in fact 2 different genes.
Another puzzling finding was that the presence of DFR 1 on a multicopy
plasmid seemed to have no effect on the TRM-sensitivity of rad 6,
rad 18 and folate depleted wild-type cells. Furthermore,
transformation of the rad 6 and rad 18 strains with the pDR509 did not
alter their sensitivity to radiation (L. Prakash, pers. comm.). In
view of the finding that DFR 1 is located on chromosome XV, it seems
unlikely that either rad 6 or rad 18 are, allelic to this gene.
No increase in the frequency of fJ- was observed in cells grown in
the presence of TRM, which is also uncharacteristic of an antifolate.
However, this may have been due to the culture conditions which lacked
all C1 metabolites. Consequently, the absence of petite induction may
have resulted from this non-specific folate depletion.
Although it is unclear why TRM does not produce the
characteristic effects of a folate antagonist in cell populations, one
interpretation of these findings may be that the target of this drug
is not dihydrofolate reductase in yeast.
129
SUMMARY AND CONCLUSIONS
The cloned dihydrofolate reductase gene (DFR 1) of S.
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cerevisiae is expressed in both bacteria and yeast. E. coli
strains containing DFR 1 were at least 5 times more resistant to
inhibition by the folate antagonist TRM. Expression of yeast
dhfr in bacteria suggests DFR 1 lacks intervening sequences to
any great extent. Furthermore, the yeast DNA fragment probably
has its own promotor as evidenced by expression of the cloned
yeast dhfr gene in both orientations in E. coli.
The functional unit of DFR 1 has been localized to a DNA
sequence of approximately 930 bp between the Pst 1 and Sal 1
cut sites. Several potential termination/poly(A) consensus
sequences were identified in 3' to an opal stop codon located 27
nucleotides from the Eco R1 cut site on the Pst 1 - Eco R1 DNA
fragment.
Yeast strains transformed with the DFR 1 multicopy plasmid
(pDRS09) are afforded greater resistance to the folate analogue
MTX than a DFR 1 integrant. This suggests a gene dosage effect.
Presence of DFR 1 does not effect the induction of~- in
wild-type or ~ad 18 yeast cell populations.
rad 6 cells exhibit a very low level of petite formation
both spontaneously and upon treatment with MTX. However, EtBr
induced p- to a level approximately 5010 of that exhibi ted by the
other 2 yeast strains.
The sensitivity of the rad mutants and wild-type yeast cells
to the folate antagonist trimethoprim was unaffected by the
presence of DFR 1 on a multicopy plasmid. Furthermore, TRM did
not induce petites in any strain tested which is uncharacteristic
of an antifolate. This may suggest that TRM has a target other
that dhfr in yeast.
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